Behavioral,O
Sciences,O
Strategies,O
to,O
deal,O
with,O
the,O
COVID,O
‐,O
19,NUMBER
Paulo,O
NADANOVSKY,O
(,O
a,O
.,O
b,O
),O
Ana,PERSON
Paula,PERSON
Pires,PERSON
dos,O
SANTOS,O
(,O
c,O
),O
Fundao,PERSON
Oswaldo,PERSON
Cruz,PERSON
Fiocruz,PERSON
.,O
Escola,PERSON
Nacional,PERSON
de,PERSON
Sade,PERSON
Pblica,PERSON
.,O
Departamento,O
de,O
Epidemiologia,PERSON
e,O
Mtodos,PERSON
Quantitativos,PERSON
em,O
Sade,O
.,O
Rio,CITY
de,CITY
Janeiro,CITY
.,O
RJ,O
.,O
Brazil,COUNTRY
.,O
Universidade,O
do,O
Estado,O
do,O
Rio,CITY
de,CITY
Janeiro,CITY
UERJ,ORGANIZATION
.,O
Instituto,ORGANIZATION
de,ORGANIZATION
Medicina,ORGANIZATION
Social,ORGANIZATION
.,O
Departamento,O
de,O
Epidemiolo,O
‐,O
gia,O
.,O
Rio,CITY
de,CITY
Janeiro,CITY
.,O
RJ,LOCATION
.,O
Brazil,COUNTRY
.,O
Universidade,O
do,O
Estado,O
do,O
Rio,PERSON
de,PERSON
Janeiro,PERSON
UERJ,ORGANIZATION
.,O
Faculdade,PERSON
de,PERSON
Odontologia,PERSON
.,O
Departamento,O
de,O
Odontologia,O
Pre,O
‐,O
ventiva,O
e,O
Comunitria,O
.,O
Rio,CITY
de,CITY
Janeiro,CITY
.,O
RJ,LOCATION
.,O
Brazil,COUNTRY
.,O
associative,O
interest,O
that,O
represents,O
a,O
conflict,O
Paulo,O
Nadanovsky,O
Submitted,O
:,O
May,DATE
20,DATE
.,DATE
2020,DATE
Last,O
revision,O
:,O
June,DATE
4,DATE
.,DATE
2020,DATE
Abstract,O
:,O
The,O
World,O
Health,ORGANIZATION
Organization,ORGANIZATION
declared,O
a,O
COVID,O
‐,O
19,NUMBER
pandemic,O
on,O
March,DATE
11,DATE
.,O
2020,DATE
.,O
when,O
there,O
were,O
4.293,NUMBER
confirmed,O
cumulative,O
deaths,O
.,O
By,O
May,DATE
17,NUMBER
.,O
2020,DATE
this,O
number,O
increased,O
to,O
315.005,NUMBER
.,O
The,O
risk,O
of,O
death,O
is,O
higher,O
above,O
the,O
age,O
of,O
60,NUMBER
.,O
but,O
there,O
are,O
many,O
deaths,O
below,O
60,NUMBER
(,O
for,O
example,O
.,O
in,O
Sao,CITY
Paulo,CITY
.,O
25,PERCENT
%,PERCENT
),O
.,O
Due,O
to,O
the,O
lack,O
of,O
a,O
vaccine,O
or,O
specific,O
treatment,O
.,O
there,O
are,O
at,O
least,O
three,NUMBER
types,O
of,O
interven,O
‐,O
tions,O
used,O
in,O
the,O
first,ORDINAL
wave,O
of,O
this,O
pandemic,O
:,O
increased,O
alert,O
‐,O
ness,O
and,O
hygiene,O
(,O
e.g.,O
Sweden,COUNTRY
),O
;,O
identification,O
and,O
isolation,O
of,O
infected,O
people,O
and,O
their,O
contacts,O
(,O
e.g.,O
South,COUNTRY
Korea,COUNTRY
),O
;,O
lockdown,O
(,O
e.g.,O
Italy,COUNTRY
),O
.,O
These,O
interventions,O
are,O
complementary,O
.,O
Choices,O
of,O
the,O
right,O
mix,O
of,O
interventions,O
will,O
vary,O
from,O
society,O
to,O
society,O
and,O
in,O
the,O
same,O
society,O
at,O
different,O
times,O
.,O
The,O
search,O
for,O
a,O
mir,O
‐,O
acle,O
drug,O
is,O
dangerous,O
because,O
it,O
is,O
based,O
on,O
the,O
mistaken,O
belief,O
that,O
any,O
treatment,O
option,O
is,O
better,O
than,O
nothing,O
.,O
Brazilian,NATIONALITY
soci,O
‐,O
ety,O
will,O
not,O
be,O
able,O
to,O
maintain,O
lockdown,O
for,O
a,O
long,O
period,O
.,O
Naturally,O
.,O
in,O
the,DATE
near,DATE
future,DATE
.,O
regardless,O
of,O
the,O
advice,O
from,O
sci,O
‐,O
entists,O
.,O
In,O
order,O
to,O
implement,O
any,O
strategy,O
aimed,O
to,O
control,O
the,O
pandemic,O
and,O
preserve,O
the,O
economy,O
.,O
the,O
country,O
needs,O
leadership,O
that,O
centralizes,O
and,O
coordinates,O
actions,O
.,O
Unfortunately,O
.,O
the,O
Brazilian,NATIONALITY
government,O
is,O
not,O
fulfilling,O
this,O
role,O
;,O
on,O
the,O
con,O
‐,O
trary,O
.,O
it,O
is,O
a,O
hindrance,O
.,O
This,O
negative,O
leadership,O
and,O
lack,O
of,O
coordination,O
are,O
causing,O
many,O
deaths,O
and,O
are,O
severely,O
damaging,O
the,O
lives,O
of,O
survivors,O
by,O
delaying,O
the,O
resuming,O
of,O
economic,O
and,O
social,O
activities,O
.,O
Keywords,O
:,O
Coronavirus,O
Infections,CAUSE_OF_DEATH
;,O
COVID,O
‐,O
19,NUMBER
;,O
Pandemics,O
;,O
Public,ORGANIZATION
Health,ORGANIZATION
;,O
Evidence,O
‐,O
Based,O
Practice,O
.,O
The,O
World,O
Health,ORGANIZATION
Organization,ORGANIZATION
(,O
WHO,O
),O
declared,O
a,O
COVID,O
‐,O
19,NUMBER
pandemic,O
.,O
the,O
dis,O
‐,O
ease,O
caused,O
by,O
the,O
new,O
coronavirus,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
(,O
Severe,O
Acute,O
Res,O
‐,O
piratory,O
Syndrome,O
‐,O
Coronavirus,O
‐,O
2,NUMBER
),O
.,O
on,O
March,DATE
11,DATE
.,O
2020.1,NUMBER
the,DATE
day,DATE
on,O
which,O
269,NUMBER
new,O
deaths,O
were,O
confirmed,O
in,O
the,O
world,O
(,O
with,O
4.293,NUMBER
cumulative,O
deaths,O
confirmed,O
as,O
of,O
that,O
date,O
),O
.,O
Brazil,COUNTRY
had,O
the,O
first,ORDINAL
recorded,O
death,O
on,O
March,DATE
17,DATE
.,DATE
2020,DATE
.,DATE
the,DATE
day,DATE
on,O
which,O
596,NUMBER
new,O
deaths,O
were,O
confirmed,O
in,O
the,O
world,O
;,O
on,O
May,DATE
17,DATE
.,DATE
2020,DATE
Brazil,COUNTRY
and,O
the,O
world,O
accumulated,O
16.118,NUMBER
and,O
315.005,NUMBER
deaths,O
.,O
respectively,O
.2,NUMBER
The,O
threat,O
of,O
COVID,O
‐,O
19,NUMBER
is,O
revealed,O
not,O
only,O
by,O
the,O
numbers,O
of,O
people,O
infected,O
and,O
deaths,O
.,O
but,O
mainly,O
by,O
the,O
number,O
of,O
suscepti,O
‐,O
ble,O
people,O
in,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,O
Strategies,O
to,O
deal,O
with,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
the,O
population,O
who,O
may,O
become,O
infected,O
and,O
the,O
rate,O
at,O
which,O
this,O
occurs,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
a,O
new,O
virus,O
to,O
which,O
the,O
human,O
population,O
has,O
no,O
immunity,O
.,O
The,O
transmission,O
oc,O
‐,O
curs,O
mainly,O
through,O
droplets,O
and,O
aerosols,O
when,O
the,O
person,O
talks,O
.,O
coughs,O
or,O
sneezes,O
.,O
The,O
incubation,O
period,O
is,O
five,DURATION
days,DURATION
(,O
median,O
),O
and,O
ranges,O
from,O
two,DURATION
to,DURATION
14,DURATION
days,DURATION
.,O
3,NUMBER
It,O
appears,O
that,O
25,PERCENT
%,PERCENT
of,O
infected,O
people,O
are,O
asymptomatic,O
.,O
i.e.,O
.,O
they,O
do,O
not,O
present,DATE
symptoms,O
dur,O
‐,O
ing,O
the,O
entire,O
period,O
of,O
infection,CAUSE_OF_DEATH
.,O
but,O
new,O
and,O
better,O
serologi,O
‐,O
cal,O
surveys,O
can,O
reveal,O
different,O
percentages,O
.,O
People,O
presenting,O
the,O
symptomatic,O
forms,O
of,O
the,O
disease,CAUSE_OF_DEATH
go,O
through,O
a,O
presymptomatic,O
phase,O
.,O
which,O
appears,O
to,O
last,O
for,O
about,DURATION
four,DURATION
days,DURATION
.,O
and,O
may,O
infect,O
other,O
people,O
during,O
this,O
phase,O
.4.5,NUMBER
It,O
seems,O
that,O
the,O
viral,O
load,O
is,O
highest,O
at,O
the,O
time,DATE
the,O
symptoms,O
appear,O
.,O
suggesting,O
that,O
in,O
‐,O
fectivity,O
peaks,O
before,O
the,O
symptoms,O
appear,O
.,O
which,O
can,O
lead,O
to,O
much,O
pre,O
‐,O
symptomatic,O
transmission,O
.6,NUMBER
Why,O
is,O
each,O
person,O
potential,O
‐,O
ly,O
responsible,O
for,O
the,O
death,O
of,O
others,O
?,O
We,O
are,O
facing,O
a,O
virus,O
with,O
relatively,O
high,O
or,O
moderate,O
transmissibility,O
and,O
apparently,O
low,O
lethality,O
(,O
infection,CAUSE_OF_DEATH
fatality,O
ratio,O
),O
.,O
although,O
over,O
60,DURATION
years,DURATION
of,O
age,O
the,O
mortality,O
among,O
symptomatic,O
cases,O
is,O
high,O
:,O
60,NUMBER
to,O
69,NUMBER
years,DURATION
4,PERCENT
%,PERCENT
;,O
70,DURATION
to,DURATION
79,DURATION
years,DURATION
old,DURATION
8,PERCENT
%,PERCENT
;,O
over,O
80,DURATION
years,DURATION
old,DURATION
15,PERCENT
%,PERCENT
.7,NUMBER
The,O
problem,O
is,O
that,O
even,O
a,O
relatively,O
low,O
lethality,O
.,O
when,O
spread,O
over,O
a,O
large,O
number,O
of,O
people,O
.,O
leads,O
to,O
a,O
large,O
number,O
of,O
deaths,O
in,O
the,O
population,O
.8,NUMBER
This,O
is,O
because,O
there,O
is,O
no,O
specific,O
effective,O
treatment,O
to,O
cure,O
or,O
prevent,O
death,O
by,O
COVID,O
‐,O
19,NUMBER
.,O
Another,O
problem,O
is,O
that,O
although,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
often,O
causes,O
asymptomatic,O
or,O
mild,O
illness,CAUSE_OF_DEATH
(,O
cough,O
.,O
fever,CAUSE_OF_DEATH
.,O
pain,O
.,O
and,O
malaise,O
),O
.,O
a,O
small,O
proportion,O
will,O
develop,O
severe,O
morbidity,O
requiring,O
specialized,O
care,O
.,O
includ,O
‐,O
ing,O
respirators,O
and,O
intensive,O
care,O
unit,O
beds,O
.,O
Even,O
in,O
the,O
absence,O
of,O
effective,O
specific,O
treatment,O
.,O
care,O
is,O
crucial,O
to,O
limit,O
suffer,O
‐,O
ing,O
.,O
In,O
other,O
words,O
.,O
the,O
probability,O
of,O
a,O
healthy,O
person,O
under,O
the,O
age,O
of,O
60,NUMBER
contracting,O
the,O
virus,O
and,O
requiring,O
hospitalization,O
is,O
small,O
.,O
However,O
.,O
as,O
there,O
are,O
millions,O
of,O
healthy,O
people,O
under,O
the,O
age,O
of,O
60,NUMBER
in,O
the,O
population,O
.,O
even,O
this,O
small,O
probability,O
leads,O
to,O
a,O
large,O
number,O
of,O
people,O
being,O
admitted,O
to,O
hospital,O
.,O
In,O
So,O
Paulo,O
.,O
between,O
March,DATE
17,DATE
and,O
April,DATE
30,DATE
.,DATE
2020,DATE
.,O
3.877,NUMBER
people,O
died,O
with,O
suspected,O
or,O
confirmed,O
COVID,O
‐,O
19,NUMBER
.,O
being,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,NUMBER
966,NUMBER
under,O
60,NUMBER
(,O
25,PERCENT
%,PERCENT
),O
and,O
2.911,NUMBER
60,NUMBER
or,O
over,O
(,O
we,O
used,O
da,O
‐,O
ta,O
from,O
Sao,CITY
Paulo,CITY
because,O
it,O
is,O
the,O
most,O
reliable,O
data,O
in,O
Brazil,COUNTRY
;,O
data,O
until,O
April,DATE
30,DATE
2020,DATE
because,O
there,O
is,O
a,O
delay,O
in,O
the,O
register,O
of,O
deaths,O
;,O
accessed,O
May,DATE
17,DATE
2020,DATE
),O
.,O
In,O
order,O
to,O
cause,O
966,NUMBER
deaths,O
.,O
the,O
number,O
of,O
people,O
in,O
this,O
age,O
range,O
who,O
were,O
infected,O
must,O
have,O
been,O
at,O
least,O
100,NUMBER
times,O
higher,O
.,O
i.e.,O
.,O
96.600,NUMBER
.,O
since,O
lethali,O
‐,O
ty,O
is,O
less,O
than,O
1,PERCENT
%,PERCENT
in,O
this,O
age,O
range,O
.,O
As,O
each,O
infected,O
person,O
in,O
‐,O
fects,O
on,O
average,O
two,NUMBER
to,O
three,NUMBER
people,O
.,O
96.600,NUMBER
infected,O
people,O
can,O
.,O
in,O
less,DURATION
than,DURATION
two,DURATION
weeks,DURATION
.,O
infect,O
241.500,NUMBER
(,O
96.600,NUMBER
x,O
2.5,NUMBER
),O
new,O
persons,O
and,O
so,O
on,O
.9,NUMBER
The,O
circulation,O
of,O
infected,O
people,O
is,O
common,O
.,O
as,O
many,O
are,O
asymptomatic,O
and,O
pre,O
‐,O
symptomatic,O
.,O
So,O
.,O
when,O
you,O
circulate,O
around,O
the,O
city,O
(,O
playing,O
football,O
in,O
the,O
park,O
or,O
on,O
the,O
beach,O
and,O
socializing,O
with,O
a,O
group,O
of,O
friends,O
),O
.,O
you,O
can,O
contract,O
the,O
virus,O
and,O
.,O
without,O
realizing,O
it,O
.,O
infect,O
two,NUMBER
to,O
three,NUMBER
people,O
.,O
When,O
your,O
infection,CAUSE_OF_DEATH
has,O
generated,O
100,NUMBER
infected,O
people,O
.,O
the,O
probability,O
of,O
a,O
person,O
among,O
those,O
100,NUMBER
dying,O
by,O
COVID,O
‐,O
19,NUMBER
is,O
high,O
.,O
So,O
.,O
the,O
proba,O
‐,O
bility,O
of,O
100,NUMBER
infected,O
people,O
generating,O
a,O
death,O
is,O
high,O
.,O
but,O
of,O
one,NUMBER
infected,O
person,O
(,O
e.g.,O
you,O
),O
dying,O
is,O
low,O
.,O
That,O
is,O
why,O
staying,O
at,O
home,O
during,O
an,O
epidemic,O
outbreak,O
.,O
where,O
the,O
number,O
of,O
infected,O
people,O
is,O
rising,O
and,O
there,O
is,O
no,O
vaccine,O
or,O
effective,O
treatment,O
.,O
is,O
an,O
altruistic,O
act,O
.10,NUMBER
How,O
do,O
we,O
know,O
whether,O
the,O
pandemic,O
is,O
We,O
must,O
understand,O
the,O
importance,O
of,O
time,O
(,O
or,O
speed,O
),O
to,O
measure,O
the,O
severity,O
of,O
the,O
COVID,O
‐,O
19,NUMBER
situation,O
.,O
The,O
number,O
of,O
deaths,O
or,O
of,O
patients,O
that,O
need,O
hospital,O
intensive,O
care,O
may,O
not,O
be,O
extraordi,O
‐,O
nary,O
if,O
we,O
use,O
an,O
annual,SET
time,O
scale,O
.,O
However,O
.,O
on,O
a,O
daily,SET
.,O
weekly,SET
and,O
possibly,O
monthly,SET
time,O
scale,O
.,O
the,O
severity,O
of,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
is,O
extraordinary,O
.,O
There,O
is,O
an,O
indicator,O
of,O
the,O
trans,O
‐,O
missibility,O
potential,O
of,O
an,O
infectious,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
called,O
R0,O
(,O
R,O
nought,O
.,O
or,O
basic,O
reproductive,O
number,O
),O
.,O
which,O
denotes,O
.,O
on,O
average,O
.,O
the,O
number,O
of,O
people,O
who,O
get,O
infected,O
by,O
each,O
infected,O
person,O
in,O
a,O
population,O
of,O
susceptible,O
individuals,O
.,O
Similarly,O
.,O
there,O
is,O
RE,O
(,O
effective,O
reproductive,O
number,O
),O
.,O
which,O
is,O
the,O
actual,O
transmissi,O
‐,O
bility,O
of,O
the,O
disease,CAUSE_OF_DEATH
during,O
the,O
epidemic,O
when,O
there,O
is,O
an,O
in,O
‐,O
creasing,O
number,O
of,O
people,O
with,O
antibodies,O
to,O
the,O
virus,O
.,O
R0,O
can,O
be,O
understood,O
as,O
what,O
can,O
potentially,O
occur,O
and,O
RE,O
what,O
actually,O
(,O
effectively,O
),O
occurs,O
.,O
The,O
only,O
difference,O
Nadanovsky,O
P,O
.,O
Santos,PERSON
APP,O
between,O
R0,O
and,O
RE,O
is,O
that,O
RE,O
is,O
not,O
dependent,O
on,O
the,O
whole,O
population,O
being,O
susceptible,O
.11,NUMBER
R0,O
depends,O
not,O
only,O
on,O
intrinsic,O
aspects,O
of,O
the,O
virus,O
.,O
but,O
also,O
on,O
environmental,O
circumstances,O
.,O
be,O
they,O
cultural,O
(,O
e.g.,O
habit,O
of,O
hugging,O
.,O
kissing,O
.,O
physical,O
contact,O
in,O
general,TITLE
),O
or,O
housing,O
(,O
e.g.,O
slums,O
with,O
small,O
houses,O
.,O
very,O
close,O
to,O
each,O
other,O
and,O
with,O
many,O
people,O
living,O
together,O
),O
.,O
In,O
addi,O
‐,O
tion,O
.,O
home,O
confinement,O
and,O
social,O
isolation,O
measures,O
also,O
influ,O
‐,O
ence,O
R0,O
.12,NUMBER
In,O
this,O
case,O
.,O
R0,O
will,O
vary,O
depending,O
on,O
economic,O
as,O
‐,O
pects,O
(,O
difficulty,O
in,O
adhering,O
to,O
the,O
recommendation,O
to,O
stay,O
at,O
home,O
.,O
as,O
there,O
is,O
a,O
need,O
to,O
work,O
daily,SET
to,O
survive,O
;,O
lack,O
of,O
access,O
to,O
piped,O
water,O
),O
and,O
on,O
social,O
aspects,O
(,O
little,O
confidence,O
formal,O
education,O
making,O
it,O
difficult,O
to,O
obtain,O
correct,O
information,O
on,O
how,O
to,O
deal,O
with,O
this,O
pandemic,O
),O
.,O
This,O
means,O
that,O
the,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
R0,O
may,O
be,O
different,O
in,O
two,NUMBER
countries,O
or,O
two,NUMBER
cities,O
even,O
if,O
the,O
virus,O
is,O
genetically,O
identical,O
in,O
those,O
places,O
.,O
The,O
lower,O
the,O
R0,O
or,O
RE,O
the,O
better,O
.,O
as,O
it,O
means,O
that,O
the,O
epidemic,O
is,O
spreading,O
less,O
.,O
Values,O
of,O
RE,O
>,O
1,NUMBER
mean,O
that,O
the,O
epidemic,O
is,O
increasing,O
.,O
RE,O
=,O
1,NUMBER
it,O
is,O
stabilized,O
and,O
RE,O
<,O
1,NUMBER
the,O
epidemic,O
is,O
decreasing,O
.,O
A,O
more,O
reliable,O
response,O
about,O
the,O
spreading,O
of,O
the,O
virus,O
in,O
Brazil,COUNTRY
will,O
come,O
when,O
serological,O
surveys,O
for,O
specific,O
antibodies,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
are,O
performed,O
periodically,O
on,O
representative,TITLE
samples,O
of,O
the,O
population,O
.,O
Fortunately,O
.,O
these,O
studies,O
are,O
already,O
being,O
conduct,O
‐,O
ed,O
.,O
The,O
first,ORDINAL
state,O
to,O
start,O
was,O
Rio,CITY
Grande,CITY
do,O
Sul,O
(,O
RS,O
),O
on,O
April,DATE
11,NUMBER
.,O
2020,DATE
and,O
four,NUMBER
phases,O
with,O
a,O
two,NUMBER
‐,O
week,DURATION
interval,O
between,O
them,O
were,O
planned,O
.13,NUMBER
In,O
the,O
first,ORDINAL
phase,O
.,O
4.189,NUMBER
people,O
were,O
tested,O
on,O
April,DATE
11,DATE
‐,DATE
13,DATE
and,O
two,NUMBER
were,O
positive,O
for,O
antibodies,O
(,O
IgM,O
and,O
IgG,O
),O
.,O
Two,DATE
weeks,DATE
later,DATE
on,O
April,DATE
25,DATE
‐,DATE
27,DATE
.,O
4.500,NUMBER
people,O
were,O
tested,O
and,O
six,NUMBER
were,O
positive,O
.,O
On,O
May,DATE
9,DATE
‐,O
11,NUMBER
.,O
4.500,NUMBER
were,O
tested,O
and,O
10,NUMBER
were,O
posi,O
‐,O
tive,O
.,O
The,O
population,O
in,O
RS,O
had,O
antibodies,O
in,O
the,O
first,ORDINAL
phase,O
.,O
0.13,PERCENT
%,PERCENT
in,O
the,O
second,ORDINAL
and,O
0.22,PERCENT
%,PERCENT
in,O
the,O
third,ORDINAL
.,O
These,O
numbers,O
trans,O
‐,O
lated,O
to,O
5.650,NUMBER
people,O
with,O
antibodies,O
in,O
RS,O
on,O
April,DATE
13,DATE
.,O
15.066,NUMBER
on,O
April,DATE
27,DATE
and,O
24.860,NUMBER
on,O
of,O
the,O
third,ORDINAL
survey,O
that,O
.,O
for,O
every,O
million,NUMBER
inhabitants,O
in,O
RS,O
.,O
2.200,NUMBER
were,O
infected,O
.,O
As,O
at,O
that,O
time,O
there,O
were,O
only,O
248,NUMBER
reported,O
cases,O
.,O
they,O
concluded,O
that,O
for,O
each,O
case,O
reported,O
in,O
the,O
RS,O
there,O
were,O
nine,NUMBER
unreported,O
the,O
case,O
fa,O
‐,O
tality,O
ratio,O
in,O
RS,O
based,O
on,O
COVID,O
‐,O
19,NUMBER
with,O
this,O
ratio,O
based,O
on,O
the,O
real,O
number,O
of,O
cases,O
estimated,O
in,O
the,O
third,ORDINAL
RS,O
survey,O
(,O
24.860,NUMBER
),O
.,O
As,O
there,O
were,O
105,NUMBER
confirmed,O
COVID,O
‐,O
19,NUMBER
deaths,O
in,O
RS,O
.,O
the,O
case,O
fa,O
‐,O
tality,O
ratio,O
(,O
lethality,O
),O
applying,O
these,O
two,NUMBER
alternative,O
denomina,O
‐,O
tors,O
was,O
4.0,PERCENT
%,PERCENT
and,O
0.42,PERCENT
%,PERCENT
.,O
respectively,O
.14,NUMBER
This,O
study,O
is,O
being,O
con,O
‐,O
ducted,O
in,O
the,O
other,O
Brazilian,NATIONALITY
states,O
(,O
133,NUMBER
cities,O
that,O
will,O
repre,O
‐,O
sent,O
the,O
dissemination,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
each,O
of,O
the,O
27,NUMBER
states,O
),O
and,O
it,O
was,O
planned,O
to,O
consist,O
of,O
three,NUMBER
surveys,O
(,O
phases,O
),O
on,O
May,DATE
12,NUMBER
.,O
May,DATE
21,DATE
and,O
June,DATE
7,DATE
.,O
with,O
33.250,NUMBER
participants,O
in,O
each,O
.,O
Non,O
‐,O
pharmacological,O
measures,O
to,O
combat,O
the,O
pandemic,O
Since,O
there,O
is,O
no,O
vaccine,O
.,O
which,O
would,O
reduce,O
the,O
number,O
of,O
susceptible,O
people,O
in,O
the,O
population,O
.,O
what,O
would,O
be,O
the,O
other,O
way,O
to,O
reduce,O
this,O
num,O
‐,O
ber,O
?,O
By,O
allowing,O
the,O
infection,CAUSE_OF_DEATH
to,O
follow,O
its,O
natural,O
course,O
so,O
that,O
after,O
a,O
period,O
of,O
time,O
the,O
number,O
of,O
people,O
who,O
have,O
created,O
antibodies,O
reaches,O
a,O
sufficient,O
proportion,O
to,O
achieve,O
RE,O
<,O
1,NUMBER
.,O
De,O
‐,O
pending,O
on,O
the,O
R0,O
.,O
there,O
is,O
a,O
proportion,O
of,O
people,O
in,O
the,O
popula,O
‐,O
tion,O
who,O
has,O
to,O
develop,O
antibodies,O
in,O
order,O
to,O
eliminate,O
the,O
dis,O
‐,O
ease,O
(,O
(,O
R0,O
‐,O
1,NUMBER
),O
/,O
R0,O
),O
.,O
For,O
example,O
.,O
if,O
COVID,O
‐,O
19,NUMBER
R0,O
=,O
3,NUMBER
in,O
Brazil,COUNTRY
.,O
when,O
67,PERCENT
%,PERCENT
of,O
the,O
population,O
has,O
created,O
antibodies,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
we,O
can,O
assume,O
that,O
the,O
epidemic,O
will,O
not,O
sustain,O
itself,O
and,O
will,O
soon,O
be,O
eliminated,O
.,O
To,O
get,O
a,O
perspective,O
of,O
what,O
this,O
means,O
in,O
real,O
life,O
.,O
let,O
us,O
look,O
at,O
what,O
happened,O
in,O
Spain,COUNTRY
during,O
the,O
most,O
critical,O
period,O
of,O
the,O
first,ORDINAL
wave,O
of,O
the,O
pandemic,O
in,O
that,O
coun,O
‐,O
try,O
.,O
There,O
.,O
between,O
March,DATE
5,DATE
and,O
May,DATE
17,DATE
.,DATE
2020,DATE
.,O
there,O
were,O
27.650,NUMBER
deaths,O
recorded,O
by,O
COVID19,O
(,O
the,O
peak,O
was,O
in,O
early,DATE
April,DATE
2020,DATE
with,O
950,NUMBER
deaths,O
recorded,O
daily,SET
),O
.,O
It,O
is,O
estimated,O
that,O
.,O
despite,O
this,O
large,O
number,O
of,O
deaths,O
.,O
only,O
5,PERCENT
%,PERCENT
of,O
the,O
population,O
has,O
been,O
in,O
‐,O
fected,O
and,O
has,O
produced,O
antibodies,O
.15,NUMBER
If,O
it,O
is,O
necessary,O
that,O
60,PERCENT
%,PERCENT
of,O
the,O
population,O
develop,O
immunity,O
in,O
order,O
to,O
achieve,O
RE,O
<,O
1,NUMBER
.,O
Spain,COUNTRY
would,O
have,O
to,O
experience,O
what,O
it,O
went,O
through,O
at,O
that,O
For,O
‐,O
tunately,O
.,O
it,O
appears,O
that,O
lockdown,O
as,O
of,O
March,DATE
14,DATE
substantially,O
reduced,O
the,O
pandemic,O
in,O
Spain,COUNTRY
and,O
there,O
was,O
already,O
a,O
reduction,O
in,O
the,O
number,O
of,O
new,O
deaths,O
detected,O
three,DURATION
weeks,DURATION
after,O
the,O
start,O
of,O
the,O
Braz,O
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,O
Strategies,O
to,O
deal,O
with,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
lockdown,O
;,O
16,NUMBER
this,O
reduction,O
has,O
shown,O
itself,O
to,O
be,O
large,O
and,O
consistent,O
since,O
then,O
.17.18,NUMBER
There,O
are,O
at,O
least,O
three,NUMBER
types,O
of,O
non,O
‐,O
pharmacological,O
interventions,O
that,O
have,O
been,O
used,O
to,O
deal,O
with,O
the,O
first,ORDINAL
wave,O
of,O
this,O
pandemic,O
:,O
a,O
),O
Increased,O
alertness,O
and,O
hygiene,O
(,O
e.g.,O
Sweden,COUNTRY
),O
;,O
b,O
),O
Identification,O
and,O
isolation,O
of,O
in,O
‐,O
fected,O
people,O
and,O
their,O
contacts,O
(,O
e.g.,O
South,COUNTRY
Korea,COUNTRY
),O
;,O
c,O
),O
Lockdown,O
(,O
e.g.,O
Italy,COUNTRY
),O
.,O
A,O
),O
Increased,O
alertness,O
and,O
hygiene,O
(,O
e.g.,O
Sweden,COUNTRY
),O
Increased,O
alertness,O
and,O
hygiene,O
are,O
changes,O
in,O
behaviour,O
aimed,O
at,O
the,O
entire,O
population,O
.,O
so,O
that,O
everybody,O
is,O
alert,O
to,O
avoid,O
ag,O
‐,O
glomeration,O
.,O
physical,O
contact,O
and,O
intensify,O
hand,O
washing,O
.,O
clean,O
‐,O
ing,O
of,O
personal,O
objects,O
and,O
surfaces,O
.,O
It,O
is,O
necessary,O
to,O
involve,O
the,O
whole,O
population,O
.,O
because,O
asymptomatic,O
and,O
pre,O
‐,O
symptomatic,O
people,O
can,O
transmit,O
the,O
virus,O
for,O
several,DURATION
days,DURATION
without,O
knowing,O
that,O
they,O
are,O
infected,O
.,O
This,O
increased,O
alertness,O
and,O
hygiene,O
were,O
also,O
adopted,O
in,O
the,O
places,O
where,O
interventions,O
b,O
and,O
c,O
above,O
were,O
applied,O
;,O
that,O
is,O
.,O
interventions,O
b,O
and,O
c,O
include,O
intervention,O
a.,O
There,O
are,O
differences,O
within,O
each,O
of,O
these,O
three,NUMBER
types,O
of,O
inter,O
‐,O
vention,O
.,O
For,O
example,O
.,O
it,O
was,O
part,O
of,O
the,O
increased,O
alertness,O
and,O
hygiene,O
in,O
South,COUNTRY
Korea,COUNTRY
(,O
in,O
Asian,NATIONALITY
countries,O
generally,O
),O
for,O
every,O
‐,O
one,NUMBER
to,O
wear,O
a,O
mask,O
on,O
the,O
streets,O
.,O
but,O
not,O
in,O
Sweden,COUNTRY
.,O
But,O
it,O
seems,O
that,O
avoiding,O
crowding,O
and,O
intensifying,O
personal,O
hygiene,O
.,O
especially,O
hand,O
washing,O
.,O
was,O
a,O
measure,O
that,O
all,O
countries,O
adopt,O
‐,O
ed,O
.,O
If,O
effective,O
.,O
this,O
is,O
possibly,O
the,O
best,O
type,O
of,O
intervention,O
because,O
it,O
keeps,O
social,O
and,O
economic,O
activities,O
going,O
and,O
does,O
not,O
spend,O
resources,O
in,O
screening,O
programs,O
to,O
identify,O
and,O
isolate,O
infected,O
people,O
.,O
To,O
be,O
effective,O
it,O
depends,O
on,O
a,O
population,O
with,O
a,O
good,O
level,O
of,O
formal,O
education,O
.,O
cooperation,O
.,O
In,O
addition,O
.,O
this,O
type,O
of,O
intervention,O
depends,O
on,O
a,O
competent,O
leadership,O
.,O
that,O
is,O
.,O
well,O
informed,O
.,O
coordinated,O
.,O
proactive,O
.,O
consistent,O
.,O
firm,O
.,O
objec,O
‐,O
tive,O
and,O
clear,O
.,O
It,O
is,O
worth,O
warning,O
though,O
.,O
that,O
among,O
the,O
Scan,O
‐,O
dinavian,O
countries,O
.,O
Sweden,COUNTRY
has,O
had,O
the,O
highest,O
number,O
of,O
deaths,O
by,O
COVID,O
‐,O
19,NUMBER
to,O
date,O
.,O
May,DATE
17,DATE
.,DATE
2020,DATE
:,O
Sweden,COUNTRY
3.674,NUMBER
;,O
Denmark,COUNTRY
543,NUMBER
;,O
Norway,COUNTRY
232,NUMBER
;,O
note,O
that,O
it,O
is,O
not,O
necessary,O
to,O
consider,O
the,O
size,O
of,O
the,O
population,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,O
to,O
compare,O
the,O
number,O
of,O
COVID,O
‐,O
19,NUMBER
deaths,O
between,O
countries,O
.19,NUMBER
The,O
overall,O
excess,O
mor,O
‐,O
tality,O
during,O
the,O
outbreaks,O
in,O
each,O
of,O
these,O
countries,O
was,O
also,O
higher,O
in,O
Sweden,COUNTRY
:,O
Sweden,COUNTRY
3.000,NUMBER
more,O
deaths,O
than,O
usual,O
(,O
29,PERCENT
%,PERCENT
),O
;,O
Den,O
‐,O
mark,O
200,NUMBER
more,O
deaths,O
(,O
6,PERCENT
%,PERCENT
),O
;,O
Norway,COUNTRY
0,NUMBER
more,O
deaths,O
(,O
0,PERCENT
%,PERCENT
),O
.20,NUMBER
B,O
),O
Iden,O
‐,O
tification,O
and,O
isolation,O
of,O
infected,O
persons,O
and,O
their,O
contacts,O
(,O
e.g.,O
South,COUNTRY
Korea,COUNTRY
),O
This,O
intervention,O
emphasizes,O
identifying,O
in,O
‐,O
fected,O
people,O
and,O
their,O
contacts,O
through,O
diagnostic,O
tests,O
for,O
virus,O
detection,O
and,O
their,O
confinement,O
for,O
a,O
period,O
of,O
two,NUMBER
to,O
three,DURATION
weeks,DURATION
.,O
This,O
intervention,O
is,O
expensive,O
.,O
difficult,O
to,O
imple,O
‐,O
ment,O
.,O
and,O
requires,O
a,O
major,O
effort,O
to,O
recruit,O
and,O
train,O
workers,O
to,O
perform,O
the,O
tests,O
and,O
the,O
population,O
to,O
adhere,O
to,O
the,O
constant,O
tests,O
(,O
which,O
involves,O
unpleasant,O
procedures,O
such,O
as,O
having,O
a,O
swab,O
introduced,O
deep,O
in,O
the,O
nose,O
or,O
the,O
throat,O
),O
.,O
The,O
development,O
of,O
complex,O
technological,O
and,O
logistical,O
resources,O
using,O
.,O
for,O
exam,O
‐,O
ple,O
.,O
connected,O
mobile,TITLE
phone,O
networks,O
and,O
testing,O
points,O
across,O
the,O
country,O
may,O
be,O
necessary,O
in,O
order,O
to,O
implement,O
efficient,O
con,O
‐,O
tact,O
tracing,O
and,O
testing,O
in,O
large,O
cities,O
.21,NUMBER
Testing,O
has,O
to,O
be,O
carried,O
out,O
frequently,O
and,O
on,O
a,O
large,O
scale,O
.,O
For,O
example,O
.,O
one,NUMBER
model,TITLE
.,O
possibly,O
one,NUMBER
of,O
the,O
most,O
parsimonious,O
.,O
estimated,O
that,O
5,NUMBER
million,NUMBER
tests,O
would,O
be,O
needed,O
initially,O
and,O
then,O
20,NUMBER
million,NUMBER
daily,SET
for,O
this,O
intervention,O
to,O
be,O
successful,O
in,O
the,O
USA,COUNTRY
.21,NUMBER
In,O
addition,O
.,O
the,O
state,O
has,O
to,O
provide,O
quarantine,O
sites,O
and,O
financial,O
aid,O
for,O
infected,O
people,O
who,O
are,O
unable,O
to,O
quarantine,O
at,O
home,O
.,O
This,O
inter,O
‐,O
vention,O
presents,O
ethical,O
challenges,O
related,O
to,O
the,O
protection,O
of,O
privacy,O
.,O
nondiscrimination,O
(,O
that,O
is,O
.,O
avoiding,O
prejudice,O
against,O
infected,O
people,O
),O
and,O
individual,O
civil,O
liberties,O
.21,NUMBER
If,O
well,O
imple,O
‐,O
mented,O
.,O
it,O
can,O
be,O
reassuring,O
(,O
people,O
feel,O
reassured,O
that,O
there,O
are,O
almost,O
no,O
infectious,O
people,O
circulating,O
between,O
them,O
),O
and,O
ef,O
‐,O
fective,O
in,O
keeping,O
the,O
virus,O
circulation,O
restricted,O
.,O
As,O
with,O
al,O
‐,O
ternative,O
a,O
above,O
.,O
this,O
type,O
of,O
intervention,O
also,O
preserves,O
so,O
‐,O
cial,O
and,O
economic,O
activities,O
in,O
the,O
country,O
.,O
C,O
),O
Lockdown,O
(,O
e.g.,O
Italy,COUNTRY
),O
Lockdown,O
includes,O
interventions,O
such,O
as,O
closing,O
trade,O
and,O
services,O
.,O
restricting,O
transport,O
and,O
closing,O
of,O
the,O
entire,O
popula,O
‐,O
tion,O
.,O
with,O
the,O
exception,O
of,O
essential,O
Nadanovsky,O
P,O
.,O
Santos,O
APP,O
workers,O
(,O
e.g.,O
health,O
and,O
food,O
professionals,O
.,O
and,O
the,O
police,O
),O
.,O
This,O
type,O
of,O
intervention,O
is,O
the,O
last,O
resort,O
in,O
the,O
impossibility,O
(,O
or,O
failure,O
),O
of,O
the,O
two,NUMBER
previous,O
Strategies,O
to,O
end,O
the,O
lockdown,O
Lockdown,O
may,O
be,O
effective,O
in,O
reducing,O
the,O
number,O
of,O
deaths,O
and,O
severe,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
but,O
it,O
is,O
not,O
a,O
realistic,O
option,O
to,O
confine,O
people,O
for,O
many,O
months,DURATION
.,O
If,O
economic,O
activity,O
becomes,O
de,O
‐,O
pressed,O
.,O
at,O
the,O
level,O
it,O
remains,O
during,O
lockdown,O
.,O
for,O
more,O
than,O
a,O
few,DURATION
months,DURATION
.,O
the,O
number,O
of,O
deaths,O
caused,O
by,O
the,O
economic,O
downturn,O
may,O
be,O
greater,O
than,O
that,O
avoided,O
by,O
COVID,O
‐,O
19.22,NUMBER
There,O
is,O
really,O
no,O
choice,O
between,O
protecting,O
health,O
or,O
protecting,O
the,O
economy,O
;,O
protecting,O
the,O
economy,O
is,O
a,O
fundamental,O
part,O
of,O
health,O
protec,O
‐,O
tion,O
.,O
Therefore,O
.,O
we,O
must,O
urgently,O
create,O
strategies,O
to,O
end,O
the,O
lockdown,O
.,O
It,O
is,O
important,O
to,O
recognize,O
that,O
there,O
are,O
positive,O
health,O
effects,O
of,O
the,O
lockdown,O
.,O
which,O
offset,O
.,O
at,O
least,O
in,O
part,O
.,O
its,O
negative,O
effects,O
.,O
such,O
as,O
a,O
reduction,O
in,O
deaths,O
and,O
hospital,O
‐,O
izations,O
due,O
to,O
:,O
traffic,O
crashes,CAUSE_OF_DEATH
;,O
violence,CAUSE_OF_DEATH
;,O
air,O
pollution,O
;,O
virus,O
‐,O
es,O
in,O
general,TITLE
;,O
gastrointestinal,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
;,O
unnecessary,O
elective,O
procedures,O
due,O
to,O
overdiagnosis,O
and,O
overtreatment,O
.,O
In,O
addition,O
.,O
the,O
such,O
as,O
hand,O
washing,O
.,O
should,O
reduce,O
the,O
circulation,O
of,O
virus,O
‐,O
es,O
and,O
microorganisms,O
in,O
general,TITLE
.,O
reducing,O
consequently,O
reducing,O
the,O
contagion,O
of,O
parents,O
.,O
grandparents,O
and,O
family,O
members,O
in,O
gen,O
‐,O
eral,O
.,O
by,O
children,O
and,O
health,O
professionals,O
.,O
Brazil,COUNTRY
began,O
the,O
lockdown,O
earlier,O
in,O
the,O
course,O
of,O
its,O
outbreak,O
(,O
at,O
least,O
Sao,PERSON
Paulo,O
and,O
Rio,CITY
de,CITY
Janeiro,CITY
),O
than,O
other,O
countries,O
such,O
as,O
Italy,COUNTRY
.,O
Spain,COUNTRY
.,O
the,O
United,COUNTRY
Kingdom,COUNTRY
and,O
the,O
USA,COUNTRY
.16,NUMBER
Therefore,O
.,O
it,O
seemed,O
that,O
there,O
would,O
be,O
fewer,O
deaths,O
and,O
severe,O
cases,O
in,O
Brazil,COUNTRY
than,O
in,O
these,O
countries,O
during,O
the,O
first,ORDINAL
wave,O
of,O
this,O
pandemic,O
.,O
It,O
seemed,O
plausible,O
that,O
the,O
exit,O
from,O
the,O
lockdown,O
in,O
Brazil,COUNTRY
could,O
occur,O
after,O
a,O
smaller,O
trauma,O
than,O
in,O
these,O
other,O
countries,O
.,O
But,O
.,O
unfortunately,O
.,O
it,O
seems,O
that,O
Brazil,COUNTRY
missed,O
the,O
opportunity,O
to,O
learn,O
from,O
the,O
countries,O
that,O
preceded,O
it,O
during,O
the,O
first,ORDINAL
wave,O
of,O
this,O
pandemic,O
.,O
giving,O
signs,O
that,O
the,O
number,O
of,O
deaths,O
here,O
will,O
be,O
even,O
higher,O
than,O
in,O
the,O
countries,O
that,O
suffered,O
the,O
most,O
.17,NUMBER
In,O
any,O
case,O
.,O
the,O
exit,O
from,O
the,O
lockdown,O
will,O
occur,O
at,O
some,O
point,O
and,O
it,O
is,O
expected,O
that,O
it,O
will,O
be,O
carried,O
out,O
cau,O
‐,O
tiously,O
.,O
Caution,O
means,O
starting,O
the,O
exit,O
only,O
when,O
there,O
is,O
an,O
indication,O
of,O
RE,O
<,O
1,NUMBER
(,O
on,O
May,DATE
8,DATE
.,DATE
2020,DATE
.,O
none,O
the,O
five,NUMBER
most,O
affected,O
Brazilian,NATIONALITY
states,O
seemed,O
to,O
have,O
been,O
able,O
to,O
reach,O
RE,O
<,O
1,NUMBER
),O
.23,NUMBER
When,O
this,O
time,O
comes,O
.,O
it,O
will,O
be,O
necessary,O
to,O
emphasize,O
the,O
in,O
‐,O
vestment,O
in,O
increased,O
alertness,O
and,O
hygiene,O
like,O
Sweden,COUNTRY
.,O
and,O
in,O
the,O
identification,O
and,O
isolation,O
of,O
infected,O
people,O
and,O
their,O
contacts,O
like,O
South,COUNTRY
Korea,COUNTRY
.,O
The,O
identification,O
and,O
isolation,O
of,O
infected,O
people,O
and,O
their,O
contacts,O
may,O
be,O
unrealistic,O
for,O
Brazil,COUNTRY
.,O
If,O
it,O
has,O
not,O
been,O
possible,O
to,O
apply,O
this,O
intervention,O
so,O
far,O
.,O
it,O
seems,O
unlikely,O
that,O
it,O
will,O
be,O
applied,O
at,O
the,O
time,DATE
of,O
relaxing,O
the,O
lockdown,O
.,O
This,O
is,O
an,O
intervention,O
that,O
demands,O
an,O
investment,O
that,O
is,O
possibly,O
beyond,O
Brazils,O
capacity,O
at,O
this,O
historical,O
.,O
so,O
‐,O
cial,O
and,O
economic,O
moment,O
.,O
If,O
there,O
is,O
sufficient,O
political,O
will,O
and,O
effort,O
from,O
society,O
to,O
apply,O
this,O
intervention,O
though,O
.,O
it,O
will,O
reduce,O
the,O
risk,O
that,O
in,O
the,DATE
coming,DATE
months,DATE
or,O
years,DURATION
we,O
will,O
have,O
to,O
resort,O
to,O
lockdown,O
periodically,O
.,O
which,O
causes,O
so,O
much,O
so,O
‐,O
cial,O
.,O
psychological,O
and,O
economic,O
harm,O
.19,NUMBER
A,O
precarious,O
alterna,O
‐,O
tive,O
.,O
in,O
the,O
absence,O
of,O
diagnostic,O
tests,O
.,O
would,O
be,O
to,O
focus,O
the,O
identification,O
of,O
infected,O
persons,O
among,O
those,O
who,O
seek,O
hospital,O
care,O
.,O
have,O
COVID,O
‐,O
19,NUMBER
confirmed,O
and,O
their,O
contacts,O
.,O
This,O
is,O
pre,O
‐,O
carious,O
because,O
it,O
does,O
not,O
identify,O
many,O
people,O
with,O
asympto,O
‐,O
matic,O
.,O
mild,O
and,O
pre,O
‐,O
symptomatic,O
disease,CAUSE_OF_DEATH
(,O
but,O
it,O
is,O
better,O
than,O
no,O
surveillance,O
at,O
all,O
),O
.,O
This,O
alternative,O
must,O
be,O
supported,O
by,O
the,O
government,O
through,O
providing,O
sites,O
for,O
quarantine,O
and,O
financial,O
help,O
for,O
people,O
who,O
are,O
unable,O
to,O
stay,O
at,O
home,O
and,O
stop,O
working,O
during,O
quarantine,O
.,O
Epidemiologic,O
surveys,O
with,O
rapid,O
serologic,O
antibody,O
tests11,O
are,O
likely,O
to,O
be,O
the,O
key,O
tool,O
to,O
help,O
us,O
deal,O
with,O
this,O
pandemic,O
.,O
which,O
could,O
last,O
until,O
2022,DATE
(,O
and,O
even,O
resur,O
‐,O
face,O
in,O
2025,DATE
),O
.12,NUMBER
These,O
tests,O
are,O
likely,O
to,O
act,O
as,O
the,O
speedometer,O
that,O
will,O
indicate,O
the,O
rate,O
of,O
virus,O
transmission,O
;,O
this,O
will,O
help,O
us,O
accelerate,O
and,O
trade,O
.,O
exiting,O
or,O
starting,O
lockdown,O
.,O
etc,O
.,O
An,O
‐,O
other,O
role,O
to,O
be,O
considered,O
for,O
serological,O
tests,O
is,O
In,O
this,O
case,O
.,O
the,O
objective,O
is,O
to,O
identify,O
people,O
in,O
the,O
population,O
who,O
are,O
able,O
to,O
leave,O
home,O
confinement,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,NUMBER
Strategies,O
to,O
deal,O
with,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
and,O
speed,O
up,O
the,O
resumption,O
of,O
economic,O
and,O
social,O
activities,O
.,O
The,O
accuracy,O
of,O
the,O
serological,O
test,O
for,O
antibodies,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
currently,DATE
in,O
use,O
in,O
Brazil,COUNTRY
the,O
usefulness,O
of,O
the,O
test,O
depends,O
on,O
the,O
prevalence,O
of,O
people,O
with,O
antibodies,O
in,O
the,O
population,O
.,O
Even,O
with,O
a,O
very,O
good,O
specificity,O
(,O
99,PERCENT
%,PERCENT
),O
a,O
positive,O
result,O
is,O
more,O
likely,O
to,O
be,O
false,O
than,O
true,O
when,O
the,O
prevalence,O
is,O
1,PERCENT
%,PERCENT
.,O
This,O
means,O
that,O
for,O
a,O
per,O
‐,O
son,O
with,O
a,O
positive,O
result,O
.,O
the,O
probability,O
of,O
not,O
having,O
anti,O
‐,O
bodies,O
is,O
greater,O
than,O
that,O
of,O
having,O
antibodies,O
.,O
In,O
possession,O
of,O
such,O
should,O
not,O
feel,O
reassured,O
.,O
as,O
they,O
are,O
more,O
likely,O
to,O
be,O
susceptible,O
than,O
immunized,O
.24,NUMBER
On,O
the,O
other,O
hand,O
.,O
in,O
a,O
population,O
with,O
10,PERCENT
%,PERCENT
or,O
20,PERCENT
%,PERCENT
of,O
people,O
with,O
antibodies,O
.,O
a,O
positive,O
result,O
in,O
this,O
test,O
shows,O
a,O
high,O
probability,O
that,O
the,O
person,O
does,O
have,O
an,O
‐,O
tibodies,O
and,O
is,O
no,O
longer,O
at,O
risk,O
of,O
becoming,O
infected,O
or,O
infec,O
‐,O
tive,O
.,O
These,O
accuracy,O
estimates,O
are,O
based,O
on,O
the,O
aggregate,O
popu,O
‐,O
lation,O
and,O
ignore,O
the,O
clinical,O
history,O
that,O
would,O
modify,O
pre,O
‐,O
test,O
probabilities,O
.,O
Within,O
the,O
general,TITLE
population,O
and,O
special,O
popula,O
‐,O
tions,O
.,O
such,O
as,O
health,O
professionals,O
.,O
there,O
are,O
individuals,O
with,O
and,O
without,O
a,O
history,O
of,O
what,O
sounds,O
like,O
COVID19,O
.,O
including,O
those,O
with,O
no,O
history,O
.,O
atypical,O
.,O
mild,O
.,O
moderate,O
and,O
severe,O
.,O
In,O
each,O
of,O
these,O
histories,O
there,O
is,O
a,O
different,O
pre,O
‐,O
test,O
probabili,O
‐,O
ty,O
.,O
which,O
can,O
vary,O
from,O
2,NUMBER
to,O
80,PERCENT
%,PERCENT
.,O
for,O
example,O
.,O
In,O
short,O
.,O
the,O
use,O
‐,O
fulness,O
of,O
this,O
type,O
of,O
test,O
to,O
assist,O
in,O
the,O
release,O
of,O
certain,O
individuals,O
.,O
that,O
is,O
.,O
in,O
providing,O
immunity,O
‐,O
based,O
(,O
or,O
perhaps,O
20,PERCENT
%,PERCENT
),O
of,O
people,O
with,O
antibodies,O
in,O
the,O
reference,O
population,O
.24,NUMBER
It,O
has,O
not,O
yet,O
been,O
proven,O
whether,O
antibodies,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
confer,O
immunity,O
and,O
if,O
so,O
.,O
for,O
how,O
long,O
.,O
Therefore,O
.,O
this,O
type,O
of,O
test,O
may,O
be,O
irrelevant,O
if,O
the,O
antibodies,O
do,O
not,O
confer,O
immunity,O
or,O
confer,O
it,O
for,O
a,O
short,O
period,O
of,O
time,O
.,O
For,O
the,O
time,O
being,O
.,O
based,O
on,O
studies,O
with,O
monkeys,O
and,O
evidence,O
of,O
other,O
viruses,O
in,O
humans,O
.,O
it,O
is,O
assumed,O
that,O
immunity,O
has,O
been,O
acquired,O
for,O
at,O
least,O
two,NUMBER
years,DURATION
.12,NUMBER
In,O
the,DATE
near,DATE
future,DATE
.,O
the,O
science,O
behind,O
this,O
type,O
of,O
test,O
is,O
expected,O
to,O
be,O
more,O
conclusive,O
.,O
Assuming,O
that,O
antibodies,O
are,O
indeed,O
neutralizing,O
the,O
virus,O
for,O
a,O
long,O
time,O
;,O
that,O
the,O
preva,O
‐,O
lence,O
of,O
people,O
with,O
antibodies,O
in,O
populations,O
is,O
greater,O
than,O
10,NUMBER
or,O
20,PERCENT
%,PERCENT
.,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,NUMBER
or,O
that,O
more,O
accurate,O
new,O
tests,O
are,O
created,O
.,O
and,O
reach,O
100,PERCENT
%,PERCENT
or,O
almost,O
100,PERCENT
%,PERCENT
specificity,O
.,O
that,O
is,O
.,O
rarity,O
or,O
absence,O
of,O
false,O
‐,O
positive,O
results,O
;,O
these,O
tests,O
can,O
be,O
a,O
valuable,O
aid,O
to,O
the,O
prudent,O
opening,O
of,O
society,O
during,O
epidemic,O
waves,O
in,O
which,O
society,O
has,O
been,O
placed,O
under,O
strict,O
norms,O
of,O
limiting,O
mobility,O
and,O
outside,O
activities,O
.,O
There,O
are,O
ethical,O
and,O
practical,O
challenges,O
that,O
will,O
need,O
to,O
be,O
addressed,O
by,O
societies,O
that,O
choose,O
to,O
issue,O
including,O
the,O
following,O
:,O
25,NUMBER
stigma,O
(,O
discrimination,O
),O
increased,O
inequality,O
in,O
favour,O
of,O
those,O
who,O
can,O
afford,O
susceptible,O
to,O
fraud,CRIMINAL_CHARGE
;,O
errors,O
in,O
the,O
test,O
that,O
would,O
lead,O
to,O
issuing,O
the,O
licence,O
to,O
people,O
who,O
should,O
not,O
obtain,O
it,O
.,O
Experts,O
in,O
bioethics,O
made,O
an,O
excellent,O
analogy,O
were,O
able,O
to,O
answer,O
convincingly,O
all,O
questions,O
and,O
concluded,O
that,O
.,O
although,O
immunity,O
‐,O
based,O
licensing,O
requires,O
care,O
for,O
implementation,O
and,O
solid,O
scientific,O
support,O
.,O
none,O
of,O
the,O
objections,O
identified,O
so,O
far,O
make,O
them,O
unethical,O
in,O
principle,O
.25,NUMBER
A,O
strategy,O
that,O
would,O
probably,O
be,O
prudent,O
.,O
fair,O
and,O
efficient,O
to,O
speed,O
up,O
exiting,O
lock,O
‐,O
down,O
is,O
as,O
follows,O
:,O
when,O
the,O
proportion,O
of,O
people,O
with,O
antibodies,O
in,O
the,O
general,TITLE
population,O
is,O
small,O
(,O
<,O
10,PERCENT
%,PERCENT
),O
.,O
emphasize,O
the,O
identi,O
‐,O
fication,O
and,O
isolation,O
of,O
the,O
infected,O
(,O
frequent,O
tests,O
to,O
detect,O
the,O
presence,O
of,O
the,O
virus,O
),O
.21,NUMBER
When,O
this,O
proportion,O
exceeds,O
10,PERCENT
%,PERCENT
.,O
also,O
emphasize,O
the,O
issuance,O
the,O
presence,O
of,O
antibodies,O
.25,NUMBER
If,O
there,O
is,O
not,O
enough,O
political,O
determination,O
and,O
coordination,O
(,O
competence,O
),O
or,O
economic,O
.,O
social,O
.,O
technological,O
or,O
cultural,O
con,O
‐,O
ditions,O
to,O
promote,O
lockdown,O
relaxation,O
through,O
virus,O
and,O
antibody,O
detection,O
tests,O
.,O
the,O
alternative,O
will,O
be,O
trial,O
and,O
error,O
type,O
of,O
relaxation,O
.,O
In,O
this,O
case,O
.,O
the,O
end,O
of,O
and,O
services,O
and,O
the,O
release,O
of,O
transportation,O
may,O
consist,O
of,O
the,O
release,O
of,O
the,O
entire,O
popu,O
‐,O
lation,O
at,O
once,DATE
at,O
a,O
given,O
time,O
.,O
Alternatively,O
.,O
opening,O
can,O
begin,O
gradually,O
.,O
for,O
example,O
.,O
in,O
weekly,SET
waves,O
.,O
directing,O
the,O
lockdown,O
relaxation,O
to,O
distinct,O
occupational,O
groups,O
.,O
For,O
example,O
.,O
it,O
may,O
initially,O
release,O
workers,O
from,O
sectors,O
that,O
depend,O
most,O
on,O
being,O
away,O
from,O
Nadanovsky,PERSON
P,PERSON
.,O
Santos,PERSON
APP,O
home,O
to,O
carry,O
out,O
their,O
activ,O
‐,O
ities,O
(,O
factory,O
workers,O
.,O
construction,O
workers,O
.,O
shopkeepers,O
.,O
etc,O
.,O
),O
and,O
later,O
those,O
who,O
are,O
able,O
to,O
carry,O
out,O
a,O
large,O
part,O
of,O
their,O
The,O
criteria,O
will,O
obviously,O
vary,O
according,O
to,O
the,O
specificities,O
of,O
each,O
city,O
.,O
state,O
and,O
country,O
.,O
The,O
trial,O
and,O
error,O
type,O
of,O
lockdown,O
relaxation,O
is,O
risky,O
because,O
a,O
large,O
number,O
of,O
suscepti,O
‐,O
ble,O
.,O
asymptomatic,O
.,O
pre,O
‐,O
symptomatic,O
and,O
infective,O
individuals,O
are,O
released,O
at,O
the,O
same,O
time,O
.,O
creating,O
a,O
social,O
environment,O
con,O
‐,O
ducive,O
to,O
virus,O
transmission,O
.,O
which,O
can,O
lead,O
to,O
uncontrolled,O
epi,O
‐,O
demic,O
and,O
in,O
a,O
short,O
time,O
the,O
need,O
for,O
new,O
closures,O
and,O
even,O
lockdown,O
.,O
The,O
advantages,O
are,O
the,O
rapid,O
and,O
vigorous,O
resumption,O
of,O
economic,O
and,O
social,O
activity,O
and,O
the,O
faster,O
increase,O
in,O
the,O
number,O
of,O
infected,O
individuals,O
who,O
will,O
produce,O
antibodies,O
.,O
con,O
‐,O
tributing,O
to,O
the,O
reduction,O
in,O
the,O
value,O
of,O
RE,O
(,O
all,O
other,O
factors,O
remaining,O
constant,O
),O
.,O
If,O
this,O
type,O
of,O
lockdown,O
relaxation,O
is,O
adopted,O
at,O
a,O
time,O
when,O
there,O
is,O
still,O
much,O
transmission,O
of,O
the,O
infection,CAUSE_OF_DEATH
.,O
it,O
can,O
cause,O
an,O
increase,O
in,O
the,O
number,O
of,O
severe,O
cases,O
above,O
what,O
the,O
health,O
services,O
would,O
be,O
able,O
to,O
take,O
;,O
for,O
exam,O
‐,O
ple,O
.,O
as,O
of,O
May,DATE
8,DATE
.,DATE
2020,DATE
.,O
it,O
was,O
estimated,O
that,O
the,O
five,NUMBER
most,O
af,O
‐,O
fected,O
Brazilian,NATIONALITY
states,O
had,O
RE,O
>,O
1,NUMBER
.,O
so,O
.,O
the,O
epidemic,O
was,O
still,O
growing,O
.23,NUMBER
If,O
the,O
number,O
of,O
new,O
cases,O
does,O
not,O
cause,O
disruption,O
to,O
the,O
health,O
service,O
and,O
a,O
relatively,O
small,O
number,O
of,O
deaths,O
oc,O
‐,O
cur,O
.,O
this,O
alternative,O
would,O
be,O
a,O
success,O
.,O
However,O
.,O
it,O
is,O
hard,O
to,O
believe,O
that,O
this,O
success,O
will,O
be,O
achieved,O
when,O
RE,O
>,O
1,NUMBER
.,O
In,O
the,O
end,O
.,O
the,O
moment,O
of,O
exiting,O
lockdown,O
will,O
not,O
really,O
be,O
a,O
moment,O
;,O
historically,O
.,O
considering,O
past,DATE
pandemics,O
.,O
the,O
end,O
of,O
a,O
pandemic,O
is,O
diffuse,O
and,O
determined,O
not,O
only,O
(,O
and,O
perhaps,O
not,O
mainly,O
),O
by,O
medical,O
and,O
health,O
considerations,O
.,O
but,O
more,O
by,O
the,O
social,O
pres,O
‐,O
sure,O
of,O
people,O
wanting,O
to,O
return,O
to,O
normal,O
life,O
.,O
The,O
population,O
is,O
becoming,O
inpatient,O
and,O
gradually,O
returning,O
to,O
normal,O
life,O
.,O
even,O
with,O
the,O
health,O
risks,O
and,O
the,O
high,O
number,O
of,O
deaths,O
.26,NUMBER
It,O
try,O
to,O
reduce,O
the,O
transmission,O
of,O
infection,CAUSE_OF_DEATH
as,O
much,O
as,O
possible,O
.,O
while,O
there,O
is,O
social,O
collaboration,O
.,O
It,O
is,O
plausible,O
that,O
the,O
world,O
will,O
have,O
to,O
deal,O
with,O
the,O
comings,O
and,O
goings,O
of,O
this,O
COVID,O
‐,O
19,NUMBER
pandemic,O
in,O
the,DURATION
next,DURATION
two,DURATION
to,DURATION
four,DURATION
years,DURATION
.12,NUMBER
There,O
may,O
be,O
critical,O
times,O
when,O
other,O
periods,O
of,O
lockdown,O
will,O
be,O
necessary,O
if,O
effective,O
treatment,O
or,O
vaccine,O
is,O
not,O
available,O
.,O
Therefore,O
.,O
it,O
is,O
important,O
that,O
we,O
not,O
only,O
in,O
this,O
first,ORDINAL
wave,O
we,O
are,O
going,O
through,O
.,O
but,O
also,O
for,O
other,O
similar,O
situations,O
in,O
the,DATE
future,DATE
.,O
Some,O
many,O
will,O
be,O
tested,O
.,O
improved,O
and,O
adapted,O
.,O
For,O
example,O
.,O
starting,O
with,O
a,O
system,O
based,O
on,O
a,O
twoweek,O
time,O
schedule,O
(,O
consid,O
‐,O
ering,O
the,O
incubation,O
period,O
of,O
the,O
virus,O
),O
.,O
10,NUMBER
‐,O
4,NUMBER
.,O
that,O
is,O
.,O
10,DURATION
days,DURATION
at,O
home,O
and,O
4,NUMBER
out,O
.27,NUMBER
are,O
alternatives,O
that,O
do,O
not,O
exclude,O
each,O
other,O
.,O
On,O
the,O
contrary,O
.,O
they,O
are,O
complementary,O
.,O
The,O
choices,O
of,O
the,O
right,O
mix,O
will,O
vary,O
from,O
society,O
to,O
society,O
and,O
in,O
the,O
same,O
society,O
at,O
different,O
times,O
.,O
Each,O
of,O
these,O
strategies,O
has,O
advan,O
‐,O
tages,O
and,O
disadvantages,O
that,O
vary,O
primarily,O
according,O
to,O
the,O
prevalence,O
of,O
susceptible,O
people,O
in,O
the,O
population,O
and,O
the,O
rate,O
of,O
infection,CAUSE_OF_DEATH
transmission,O
.,O
Other,O
important,O
variables,O
that,O
should,O
be,O
considered,O
are,O
:,O
available,O
resources,O
(,O
diagnostic,O
tests,O
.,O
places,O
for,O
physical,O
isolation,O
.,O
health,O
facilities,O
to,O
care,O
for,O
severe,O
cas,O
‐,O
es,O
),O
;,O
socioeconomic,O
conditions,O
(,O
financial,O
reserves,O
to,O
sustain,O
drastic,O
reduction,O
in,O
economic,O
activity,O
.,O
housing,O
and,O
sanitation,O
conditions,O
.,O
population,O
density,O
),O
;,O
culture,O
(,O
discipline,O
.,O
confidence,O
and,O
social,O
norms,O
.,O
hygiene,O
habits,O
),O
.,O
Scientific,O
evidence,O
during,O
the,O
It,O
is,O
understandable,O
that,O
in,O
the,O
face,O
of,O
a,O
pandemic,O
like,O
COVID,O
‐,O
19,NUMBER
.,O
the,O
population,O
.,O
the,O
media,O
and,O
health,O
professionals,O
are,O
anxious,O
to,O
obtain,O
information,O
about,O
diagnostic,O
tests,O
.,O
treatment,O
alternatives,O
and,O
the,O
prognosis,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
As,O
it,O
is,O
an,O
un,O
‐,O
known,O
disease,CAUSE_OF_DEATH
.,O
series,O
studies,O
.,O
The,O
problem,O
is,O
that,O
.,O
in,O
the,O
eager,O
‐,O
ness,O
to,O
obtain,O
quick,O
answers,O
.,O
these,O
case,O
series,O
have,O
been,O
used,O
to,O
gather,O
information,O
about,O
the,O
effectiveness,O
of,O
different,O
treat,O
‐,O
ments,O
.,O
However,O
.,O
this,O
study,O
design,O
is,O
a,O
precarious,O
and,O
rudimentary,O
way,O
of,O
evaluating,O
the,O
effectiveness,O
of,O
treatments,O
.,O
with,O
serious,O
consequences,O
.,O
including,O
the,O
large,O
‐,O
scale,O
adoption,O
of,O
treatments,O
that,O
can,O
increase,O
morbidity,O
and,O
risk,O
of,O
death,O
.,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,O
Strategies,O
to,O
deal,O
with,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
COVID,O
‐,O
19,DATE
may,DATE
be,O
an,O
unknown,O
disease,CAUSE_OF_DEATH
.,O
but,O
its,O
consequences,O
are,O
known,O
to,O
doctors,O
.,O
For,O
example,O
.,O
fever,CAUSE_OF_DEATH
.,O
pain,O
.,O
shortness,O
of,O
breath,O
.,O
and,O
the,O
other,O
symptoms,O
related,O
to,O
COVID,O
‐,O
19,NUMBER
are,O
familiar,O
situa,O
‐,O
tions,O
that,O
doctors,O
are,O
used,O
to,O
dealing,O
with,O
.,O
The,O
clinical,O
manage,O
‐,O
ment,O
of,O
various,O
diseases,CAUSE_OF_DEATH
.,O
not,O
only,O
COVID,O
‐,O
19,NUMBER
.,O
consists,O
of,O
offering,O
palliative,O
and,O
supportive,O
care,O
.,O
Often,O
it,O
is,O
the,O
patients,O
own,O
de,O
‐,O
fensive,O
mechanisms,O
that,O
react,O
effectively,O
.,O
independently,O
of,O
the,O
medical,O
treatment,O
received,O
.,O
With,O
COVID,O
‐,O
19,NUMBER
it,O
is,O
no,O
different,O
.,O
The,O
vast,O
majority,O
of,O
patients,O
react,O
and,O
recover,O
from,O
the,O
In,O
addition,O
.,O
there,O
are,O
medical,O
and,O
pharmacological,O
resources,O
to,O
help,O
patients,O
cope,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
such,O
as,O
analgesics,O
.,O
antipyretics,O
.,O
oxygen,O
masks,O
.,O
mechanical,O
respirators,O
;,O
these,O
resources,O
can,O
be,O
lifesaving,O
.,O
There,O
is,O
then,O
a,O
standard,O
care,O
to,O
help,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
Therefore,O
.,O
the,O
question,O
we,O
have,O
to,O
answer,O
is,O
the,O
following,O
:,O
do,O
patients,O
who,O
receive,O
a,O
certain,O
drug,O
(,O
any,O
new,O
drug,O
or,O
an,O
existing,O
drug,O
.,O
but,O
not,O
yet,O
used,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
),O
.,O
in,O
addition,O
to,O
the,O
standard,O
care,O
.,O
show,O
improved,O
prognosis,O
of,O
COVID,O
‐,O
19,NUMBER
(,O
that,O
is,O
.,O
reduced,O
risk,O
of,O
dying,O
.,O
sequelae,O
or,O
length,O
of,O
hospital,O
stay,O
),O
in,O
comparison,O
to,O
patients,O
who,O
receive,O
standard,O
care,O
only,O
?,O
Let,O
us,O
see,O
how,O
case,O
series,O
can,O
not,O
answer,O
this,O
question,O
.,O
For,O
example,O
.,O
it,O
may,O
be,O
that,O
the,O
risk,O
of,O
dying,O
in,O
hospitalized,O
patients,O
infected,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
who,O
receive,O
standard,O
care,O
is,O
8,PERCENT
%,PERCENT
.,O
A,O
drug,O
.,O
in,O
addition,O
to,O
standard,O
care,O
.,O
would,O
have,O
to,O
reduce,O
this,O
risk,O
from,O
8,PERCENT
%,PERCENT
to,O
.,O
for,O
example,O
.,O
4,PERCENT
%,PERCENT
to,O
be,O
considered,O
effective,O
.,O
Imagine,O
a,O
doctor,TITLE
who,O
treated,O
100,NUMBER
patients,O
with,O
standard,O
care,O
associated,O
with,O
this,O
drug,O
.,O
He,O
noticed,O
that,O
only,O
8,NUMBER
that,O
he,O
treated,O
100,NUMBER
patients,O
with,O
the,O
drug,O
and,O
only,O
8,NUMBER
died,O
.,O
concluding,O
that,O
the,O
drug,O
is,O
a,O
success,O
.,O
As,O
there,O
were,O
no,O
patients,O
receiving,O
only,O
the,O
standard,O
care,O
.,O
he,O
could,O
not,O
realize,O
that,O
even,O
without,O
the,O
drug,O
the,O
number,O
of,O
pa,O
‐,O
tients,O
dying,O
would,O
also,O
be,O
8,NUMBER
.,O
The,O
lack,O
of,O
a,O
comparison,O
group,O
makes,O
the,O
case,O
series,O
a,O
precarious,O
modality,O
of,O
study,O
design,O
to,O
discover,O
effective,O
treatments,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
As,O
there,O
is,O
no,O
known,O
effective,O
treatment,O
specific,O
to,O
COVID,O
‐,O
19,NUMBER
.,O
a,O
source,O
of,O
information,O
may,O
be,O
the,O
experience,O
and,O
feeling,O
of,O
the,O
physicians,O
when,O
evaluat,O
‐,O
ing,O
each,O
patient,O
individually,O
(,O
gut,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,NUMBER
feeling,O
),O
.,O
This,O
lack,O
of,O
evidence,O
allows,O
the,O
ethical,O
use,O
of,O
experi,O
‐,O
mental,O
treatments,O
.,O
still,O
without,O
scientific,O
proof,O
of,O
effective,O
‐,O
ness,O
.,O
the,O
so,O
‐,O
called,O
compassionate,O
use,O
.29,NUMBER
This,O
experimental,O
situa,O
‐,O
tion,O
should,O
be,O
made,O
explicit,O
and,O
shared,O
by,O
the,O
doctor,TITLE
with,O
the,O
patient,O
and,O
the,O
patients,O
family,O
in,O
order,O
to,O
decide,O
whether,O
the,O
doctor,TITLE
will,O
only,O
provide,O
the,O
standard,O
care,O
or,O
associate,O
it,O
with,O
an,O
experimental,O
drug,O
.,O
The,O
problem,O
is,O
that,O
there,O
are,O
physicians,O
who,O
can,O
not,O
conceive,O
that,O
something,O
they,O
believe,O
in,O
so,O
much,O
has,O
to,O
be,O
considered,O
an,O
experimental,O
treatment,O
.,O
The,O
search,O
for,O
effec,O
‐,O
tive,O
treatments,O
or,O
preventive,O
measures,O
should,O
rely,O
on,O
the,O
random,O
‐,O
ized,O
controlled,O
trial,O
(,O
RCT,O
),O
.,O
This,O
is,O
the,O
study,O
design,O
that,O
pro,O
‐,O
vides,O
the,O
most,O
robust,O
and,O
reliable,O
evidence,O
.,O
At,O
this,O
moment,O
of,O
so,O
much,O
doubt,O
and,O
fear,O
.,O
the,O
RCT,O
should,O
be,O
emphasized,O
even,O
more,O
.,O
It,O
is,O
worth,O
noting,O
that,O
one,NUMBER
of,O
the,O
frustrations,O
usually,O
associated,O
with,O
the,O
RCT,ORGANIZATION
is,O
the,O
long,O
time,O
it,O
takes,O
to,O
be,O
performed,O
.,O
especial,O
‐,O
ly,O
when,O
researchers,O
have,O
to,O
follow,O
participants,O
for,O
long,O
periods,O
of,O
time,O
until,O
the,O
outcomes,O
of,O
interest,O
occur,O
.,O
In,O
the,O
case,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
because,O
it,O
is,O
a,O
fast,O
course,O
disease,CAUSE_OF_DEATH
.,O
the,O
outcomes,O
of,O
interest,O
(,O
e.g.,O
.,O
death,O
.,O
length,O
of,O
stay,O
and,O
lung,O
damage,O
),O
occur,O
within,O
one,NUMBER
or,O
two,DURATION
months,DURATION
;,O
this,O
allows,O
the,O
RCT,O
to,O
be,O
completed,O
in,O
a,O
relatively,O
short,O
time,O
.,O
Better,O
than,O
one,NUMBER
RCT,ORGANIZATION
are,O
all,O
the,O
RCTs,O
already,O
of,O
RCT,O
provides,O
the,O
best,O
answer,O
about,O
treatment,O
to,O
com,O
‐,O
plete,O
.,O
so,O
we,O
have,O
seen,O
an,O
increasing,O
number,O
provided,O
that,O
all,O
steps,O
are,O
maintained,O
and,O
there,O
is,O
no,O
loss,O
of,O
quality,O
during,O
the,O
process,O
.,O
This,O
is,O
possible,O
automated,O
and,O
when,O
experienced,O
re,O
‐,O
searchers,O
dedicate,O
their,O
time,O
exclusively,O
to,O
this,O
work,O
.30,NUMBER
Pre,O
‐,O
prints,O
is,O
another,O
method,O
for,O
sharing,O
scientific,O
evidence,O
during,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
.,O
These,O
are,O
Preprints,O
in,O
the,O
health,O
area,O
have,O
recently,DATE
gained,O
more,O
attention,O
because,O
the,O
storage,O
capacity,O
of,O
the,O
repositories,O
is,O
much,O
greater,O
than,O
that,O
of,O
conventional,O
Nadanovsky,O
P,O
.,O
Santos,PERSON
APP,O
available,O
study,O
results,O
that,O
can,O
have,O
an,O
immediate,O
impact,O
on,O
the,O
management,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
Many,O
health,O
policies,O
during,O
the,O
pandemic,O
are,O
being,O
guided,O
by,O
preprints,O
.32,NUMBER
The,O
negative,O
side,O
of,O
the,O
preprint,O
is,O
publication,O
of,O
studies,O
with,O
gross,O
methodological,O
errors,O
that,O
threaten,O
confidence,O
in,O
the,O
re,O
‐,O
sults,O
.,O
The,O
positive,O
side,O
is,O
the,O
rapid,O
dissemination,O
of,O
results,O
and,O
visibility,O
.,O
allowing,O
the,O
scientific,O
community,O
to,O
have,O
quick,O
access,O
to,O
the,O
study,O
and,O
make,O
their,O
critiques,O
and,O
contributions,O
openly,O
.,O
An,O
extraordinary,O
amount,O
of,O
research,O
has,O
been,O
carried,O
out,O
recently,DATE
on,O
several,O
topics,O
related,O
to,O
COVID,O
‐,O
19,NUMBER
.,O
While,O
this,O
shows,O
the,O
admirable,O
effort,O
and,O
vigour,O
of,O
the,O
scientific,O
community,O
to,O
react,O
quickly,O
to,O
seek,O
solutions,O
.,O
it,O
also,O
reveals,O
a,O
lack,O
of,O
coor,O
‐,O
dination,O
to,O
minimize,O
duplication,O
of,O
efforts,O
and,O
maximize,O
avail,O
‐,O
able,O
resources,O
.,O
For,O
example,O
.,O
there,O
are,O
more,O
than,O
1.500,NUMBER
records,O
of,O
ongoing,O
studies,O
related,O
Of,O
these,O
.,O
more,O
than,O
900,NUMBER
are,O
RCTs,O
.,O
of,O
which,O
more,O
than,O
400,NUMBER
are,O
currently,DATE
recruiting,O
participants,O
.,O
Many,O
studies,O
with,O
the,O
same,O
hypotheses,O
lead,O
to,O
a,O
competition,O
for,O
par,O
‐,O
ticipants,O
.,O
besides,O
being,O
a,O
missed,O
opportunity,O
to,O
test,O
different,O
hypotheses,O
.34,NUMBER
There,O
are,O
several,O
small,O
and,O
isolated,O
RCTs,MISC
testing,O
the,O
same,O
drugs,CRIMINAL_CHARGE
.,O
some,O
of,O
which,O
will,O
probably,O
not,O
manage,O
to,O
recruit,O
enough,O
patients,O
to,O
be,O
able,O
to,O
detect,O
differences,O
between,O
the,O
groups,O
being,O
compared,O
.35,NUMBER
It,O
would,O
be,O
better,O
to,O
perform,O
multicen,O
‐,O
tric,O
.,O
adaptive,O
RCTs,MISC
.,O
which,O
test,O
a,O
range,O
of,O
potential,O
treatments,O
simultaneously,O
and,O
are,O
able,O
to,O
recruit,O
patients,O
with,O
different,O
profiles,O
and,O
varied,O
clinical,O
conditions,O
more,O
quickly,O
.,O
An,O
example,O
of,O
this,O
type,O
of,O
RCT,O
is,O
the,O
Recovery,O
Trial,O
.36,NUMBER
In,O
addition,O
.,O
it,O
is,O
important,O
that,O
there,O
is,O
a,O
monitoring,O
system,O
to,O
avoid,O
publication,O
bias,O
.,O
There,O
are,O
attempts,O
to,O
create,O
a,O
register,O
that,O
captures,O
all,O
RCTs,O
related,O
to,O
COVID,O
‐,O
19.37,NUMBER
There,O
has,O
also,O
been,O
much,O
duplication,O
of,O
effort,O
in,O
conducting,O
May,DATE
18,DATE
.,DATE
2020,DATE
.,O
there,O
were,O
925,NUMBER
records,O
of,O
systematic,O
50,NUMBER
aim,O
to,O
evaluate,O
the,O
effectiveness,O
and,O
/,O
or,O
safety,O
of,O
chloroquine,O
/,O
hydroxychloroquine,O
(,O
alone,O
or,O
combined,O
with,O
another,O
drug,O
),O
in,O
treating,O
COVID,O
‐,O
19.38,NUMBER
The,O
frantic,O
search,O
for,O
a,O
miracle,O
drug,O
is,O
dangerous,O
because,O
it,O
is,O
based,O
on,O
and,O
leads,O
to,O
the,O
mistak,O
‐,O
en,O
belief,O
that,O
any,O
treatment,O
option,O
is,O
better,O
than,O
nothing,O
.,O
after,O
all,O
.,O
what,O
harm,O
can,O
a,O
drug,O
do,O
when,O
there,O
is,O
no,O
other,O
treatment,O
op,O
‐,O
tion,O
available,O
?,O
However,O
.,O
it,O
is,O
not,O
true,O
that,O
there,O
is,O
nothing,O
.,O
As,O
argued,O
already,O
.,O
there,O
is,O
the,O
standard,O
care,O
and,O
the,O
natural,O
de,O
‐,O
fence,O
mechanisms,O
of,O
the,O
individual,O
against,O
the,O
disease,CAUSE_OF_DEATH
.,O
In,O
addi,O
‐,O
tion,O
.,O
medications,O
have,O
adverse,O
effects,O
.,O
often,O
severe,O
.,O
and,O
only,O
by,O
carrying,O
out,O
an,O
RCT,O
is,O
it,O
possible,O
to,O
know,O
whether,O
a,O
medicine,O
does,O
more,O
good,O
than,O
harm,O
.,O
That,O
is,O
.,O
when,O
a,O
drug,O
with,O
an,O
unknown,O
clinical,O
effect,O
(,O
or,O
known,O
.,O
but,O
in,O
patients,O
with,O
other,O
diseases,CAUSE_OF_DEATH
),O
is,O
administered,O
to,O
patients,O
with,O
severe,O
diseases,CAUSE_OF_DEATH
.,O
such,O
as,O
COVID,O
‐,O
19,NUMBER
.,O
there,O
is,O
no,O
way,O
to,O
know,O
whether,O
the,O
patients,O
have,O
bene,O
‐,O
fited,O
or,O
harmed,O
themselves,O
unless,O
they,O
have,O
been,O
compared,O
to,O
a,O
control,O
group,O
.39,NUMBER
The,O
case,O
of,O
chloroquine,O
and,O
hydroxychlorine,O
is,O
emblematic,O
.,O
One,NUMBER
of,O
the,O
main,O
appeals,O
of,O
these,O
drugs,CRIMINAL_CHARGE
is,O
that,O
they,O
have,O
been,O
used,O
for,O
many,O
years,DURATION
to,O
treat,O
patients,O
with,O
malaria,CAUSE_OF_DEATH
.,O
lu,O
‐,O
pus,O
.,O
rheumatoid,O
arthritis,O
and,O
other,O
autoimmune,O
diseases,CAUSE_OF_DEATH
.,O
This,O
would,O
already,O
ensure,O
their,O
safety,O
.,O
However,O
.,O
this,O
is,O
indirect,O
evi,O
‐,O
dence,O
:,O
they,O
may,O
be,O
safe,O
for,O
those,O
.,O
but,O
harmful,O
for,O
COVID19,O
pa,O
‐,O
tients,O
.,O
Nevertheless,O
.,O
in,O
the,DURATION
last,DURATION
few,DURATION
months,DURATION
they,O
have,O
gained,O
prominence,O
.,O
as,O
some,O
physicians,O
and,O
researchers,O
have,O
begun,O
to,O
con,O
‐,O
sider,TITLE
them,O
as,O
an,O
option,O
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
In,O
March,DATE
2020,DATE
.,O
the,O
WHO,ORGANIZATION
approved,O
studies,O
with,O
these,O
drugs,CRIMINAL_CHARGE
for,O
the,O
treatment,O
of,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
World,O
leaders,O
were,O
enthusiastic,O
about,O
these,O
drugs,CRIMINAL_CHARGE
and,O
advocated,O
that,O
they,O
would,O
be,O
the,O
cure,O
for,O
COVID,O
‐,O
19,NUMBER
;,O
this,O
caused,O
a,O
frantic,O
search,O
for,O
these,O
drugs,CRIMINAL_CHARGE
in,O
pharma,O
‐,O
cies,O
.,O
leaving,O
patients,O
with,O
other,O
diseases,CAUSE_OF_DEATH
without,O
access,O
to,O
them,O
.,O
Promising,O
in,O
vitro,O
studies,O
and,O
preliminary,O
results,O
of,O
clinical,O
studies,O
with,O
poor,O
methods,O
led,O
to,O
a,O
distorted,O
view,O
of,O
re,O
‐,O
ality,O
.,O
causing,O
many,O
physicians,O
.,O
the,O
media,O
and,O
the,O
population,O
to,O
believe,O
in,O
this,O
miracle,O
drug,O
.,O
There,O
are,O
several,O
reports,O
on,O
so,O
‐,O
cial,O
networks,O
of,O
people,O
claiming,O
that,O
they,O
have,O
been,O
saved,O
by,O
chloroquine,O
or,O
hydroxychloroquine,O
.,O
Obviously,O
.,O
no,O
individual,O
can,O
know,O
whether,O
or,O
not,O
he,O
was,O
saved,O
by,O
some,O
treatment,O
.,O
because,O
it,O
is,O
not,O
possible,O
to,O
know,O
whether,O
he,O
would,O
have,O
survived,O
or,O
recovered,O
in,O
the,O
absence,O
of,O
the,O
treatment,O
.,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,NUMBER
Strategies,O
to,O
deal,O
with,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
This,O
unscientific,O
atmosphere,O
.,O
fostered,O
by,O
some,O
political,O
leaders,O
.,O
physicians,O
and,O
researchers,O
.,O
makes,O
the,O
execution,CAUSE_OF_DEATH
of,O
RCTs,O
difficult,O
.,O
People,O
hear,O
in,O
the,O
media,O
that,O
chloroquine,O
and,O
hydroxychloroquine,O
are,O
effec,O
‐,O
tive,O
and,O
safe,O
.,O
Thus,O
.,O
patients,O
and,O
family,O
members,O
may,O
not,O
agree,O
to,O
participate,O
in,O
studies,O
where,O
they,O
will,O
be,O
randomly,O
allocated,O
ei,O
‐,O
ther,O
to,O
chloroquine,O
/,O
hydroxychloroquine,O
.,O
or,O
another,O
drug,O
or,O
a,O
placebo,O
.40,NUMBER
Who,O
will,O
agree,O
to,O
receive,O
another,O
drug,O
or,O
a,O
placebo,O
when,O
an,O
effective,O
and,O
safe,O
drug,O
is,O
available,O
?,O
Unfortunately,O
.,O
many,O
of,O
the,O
studies,O
conducted,O
on,O
COVID,O
‐,O
19,NUMBER
used,O
poor,O
methods,O
.,O
in,O
‐,O
cluding,O
those,O
that,O
aimed,O
to,O
evaluate,O
the,O
effectiveness,O
of,O
chloro,O
‐,O
quine,O
and,O
resources,O
.,O
41,NUMBER
Several,O
clinical,O
studies,O
were,O
conducted,O
without,O
a,O
control,O
group,O
.,O
There,O
was,O
also,O
a,O
comparison,O
with,O
a,O
his,O
‐,O
torical,O
control,O
group,O
.,O
not,O
internal,O
to,O
the,O
study,O
.,O
which,O
eliminat,O
‐,O
ed,O
the,O
crucial,O
role,O
of,O
randomization,O
.42,NUMBER
In,O
many,O
studies,O
there,O
was,O
also,O
no,O
blinding,O
of,O
the,O
assessment,O
of,O
the,O
outcome,O
.,O
and,O
often,O
the,O
outcomes,O
used,O
were,O
subjective,O
.,O
such,O
as,O
improvement,O
of,O
symptoms,O
or,O
radiological,O
imaging35,O
.,O
safety,O
of,O
hydroxychloroquine,O
and,O
chloro,O
‐,O
quine,O
for,O
COVID,O
‐,O
1943,DATE
included,O
.,O
so,O
far,O
.,O
120,NUMBER
comparative,O
clinical,O
studies,O
.,O
but,O
109,NUMBER
are,O
still,O
ongoing,O
.,O
so,O
the,O
results,O
refer,O
to,O
11,NUMBER
studies,O
with,O
available,O
data,O
:,O
three,NUMBER
randomized,O
open,O
clinical,O
tri,O
‐,O
als,O
(,O
China,COUNTRY
),O
.,O
one,NUMBER
non,O
‐,O
randomized,O
clinical,O
trial,O
(,O
France,COUNTRY
),O
.,O
one,NUMBER
prospective,O
cohort,O
(,O
China,COUNTRY
),O
and,O
six,NUMBER
retrospective,O
cohort,O
(,O
USA,COUNTRY
.,O
United,COUNTRY
Arab,COUNTRY
Emirates,COUNTRY
.,O
China,COUNTRY
and,O
multinational,O
),O
.,O
All,O
studies,O
pre,O
‐,O
sented,O
limited,O
methodological,O
quality,O
and,O
were,O
heterogeneous,O
re,O
‐,O
garding,O
several,O
aspects,O
.,O
such,O
as,O
study,O
design,O
(,O
randomized,O
and,O
non,O
‐,O
randomized,O
),O
.,O
outcomes,O
(,O
negative,O
viral,O
load,O
.,O
radiological,O
pro,O
‐,O
gression,O
.,O
time,O
for,O
clinical,O
improvement,O
.,O
need,O
for,O
mechanical,O
ven,O
‐,O
tilation,O
.,O
intensive,O
care,O
unit,O
lengths,O
of,O
stay,O
.,O
adverse,O
effects,O
.,O
mortality,O
),O
.,O
severity,O
of,O
disease,CAUSE_OF_DEATH
(,O
mild,O
or,O
critical,O
),O
;,O
dose,O
of,O
hy,O
‐,O
droxychloroquine,O
(,O
200,NUMBER
.,O
400,NUMBER
and,O
600,NUMBER
mg,O
/,O
day,DURATION
),O
;,O
method,O
of,O
data,O
analy,O
‐,O
sis,O
(,O
intention,O
to,O
treat,O
and,O
per,O
The,O
results,O
of,O
these,O
studies,O
are,O
somewhat,O
controversial,O
and,O
the,O
risk,O
of,O
bias,O
is,O
high,O
.,O
which,O
com,O
‐,O
promises,O
the,O
confidence,O
in,O
the,O
results,O
.,O
Therefore,O
.,O
the,O
efficacy,O
and,O
safety,O
of,O
hydroxychloroquine,O
and,O
chloroquine,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
are,O
still,O
uncertain,O
and,O
we,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,NUMBER
should,O
wait,O
for,O
the,O
results,O
of,O
ongoing,O
randomized,O
clinical,O
trials,O
for,O
a,O
better,O
understanding,O
of,O
the,O
effects,O
of,O
this,O
drug,O
in,O
pa,O
‐,O
tients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
Given,O
the,O
emergency,O
situation,O
and,O
the,O
search,O
for,O
effective,O
treatments,O
.,O
other,O
drugs,CRIMINAL_CHARGE
used,O
for,O
other,O
dis,O
‐,O
eases,O
have,O
been,O
studied,O
and,O
identified,O
as,O
possible,O
treatment,O
al,O
‐,O
ternatives,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
among,O
them,O
remdesivir,O
.,O
ivermectin,O
and,O
heparins,O
.,O
However,O
.,O
so,O
far,O
.,O
there,O
is,O
not,O
enough,O
evidence,O
to,O
estab,O
‐,O
lish,O
the,O
real,O
harms,O
and,O
benefits,O
of,O
these,O
drugs,CRIMINAL_CHARGE
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19.44.45.46,NUMBER
There,O
are,O
many,O
studies,O
in,O
progress,O
and,O
.,O
as,O
new,O
evidence,O
becomes,O
available,O
.,O
recommendations,O
on,O
the,O
use,O
of,O
these,O
drugs,CRIMINAL_CHARGE
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19,DATE
may,DATE
change,O
.,O
At,O
this,O
time,O
of,O
crisis,O
.,O
world,O
leaders,O
.,O
public,O
health,O
kinds,O
of,O
media,O
must,O
be,O
careful,O
to,O
seek,O
and,O
disseminate,O
reliable,O
information,O
in,O
order,O
not,O
to,O
support,O
the,O
use,O
of,O
therapies,O
of,O
unproven,O
effectiveness,O
.,O
Their,O
claims,O
influence,O
the,O
belief,O
and,O
behaviour,O
of,O
the,O
popula,O
‐,O
tion,O
.,O
leading,O
.,O
for,O
example,O
.,O
to,O
an,O
increase,O
in,O
internet,O
searches,O
for,O
purchasing,O
these,O
unproven,O
drugs,CRIMINAL_CHARGE
.47,NUMBER
In,O
the,O
absence,O
of,O
evidence,O
of,O
effectiveness,O
and,O
safety,O
of,O
a,O
drug,O
.,O
standard,O
treatment,O
may,O
be,O
the,O
best,O
option,O
.,O
We,O
must,O
be,O
careful,O
not,O
to,O
fall,O
into,O
the,O
tempta,O
‐,O
tion,O
to,O
give,O
in,O
to,O
obscurantism,O
and,O
weaken,O
science,O
.,O
However,O
.,O
as,O
we,O
have,O
already,O
pointed,O
out,O
.,O
there,O
are,O
two,NUMBER
perspectives,O
that,O
we,O
must,O
accommodate,O
:,O
the,O
individual,O
case,O
of,O
each,O
doctor,TITLE
‐,O
patient,O
dyad,O
and,O
public,O
policy,O
.,O
On,O
the,O
one,NUMBER
hand,O
.,O
doctors,O
may,O
face,O
difficult,O
clinical,O
situations,O
where,O
the,O
patient,O
is,O
getting,O
sicker,O
and,O
she,O
feels,O
that,O
she,O
should,O
try,O
a,O
specific,O
medication,O
beyond,O
the,O
stan,O
‐,O
dard,O
care,O
.,O
In,O
such,O
cases,O
.,O
with,O
the,O
consent,O
of,O
the,O
family,O
and,O
awareness,O
of,O
the,O
uncertainties,O
regarding,O
effectiveness,O
and,O
safe,O
‐,O
ty,O
.,O
the,O
doctor,TITLE
could,O
prescribe,O
these,O
medications,O
as,O
a,O
last,O
re,O
‐,O
sort,O
.,O
On,O
the,O
other,O
hand,O
.,O
it,O
is,O
irresponsible,O
to,O
adopt,O
a,O
public,O
policy,O
for,O
the,O
prescription,O
of,O
any,O
drug,O
without,O
proven,O
benefits,O
and,O
safety,O
from,O
RCTs,O
.,O
In,O
addition,O
to,O
the,O
extensive,O
search,O
for,O
treatment,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
many,O
researchers,O
are,O
seeking,O
an,O
effective,O
vaccine,O
.,O
There,O
are,O
more,O
than,O
100,NUMBER
vaccines,O
being,O
developed,O
.48,NUMBER
In,O
‐,O
ternational,O
scientific,O
leaders,O
and,O
experts,O
in,O
infectious,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
epidemiology,O
believe,O
Nadanovsky,PERSON
P,PERSON
.,O
Santos,PERSON
APP,O
that,O
the,O
only,O
way,O
to,O
get,O
back,O
to,O
normal,O
life,O
will,O
be,O
when,O
an,O
effective,O
vaccine,O
is,O
available,O
for,O
the,O
entire,O
world,O
population,O
.12,NUMBER
The,O
production,O
of,O
a,O
vaccine,O
is,O
a,O
time,O
‐,O
consuming,O
process,O
and,O
obtaining,O
a,O
vaccine,O
with,O
‐,O
in,O
a,O
period,O
of,O
one,DURATION
to,DURATION
two,DURATION
years,DURATION
would,O
be,O
unprecedented,O
.,O
The,O
safe,O
‐,O
ty,O
of,O
the,O
vaccine,O
is,O
a,O
crucial,O
aspect,O
to,O
be,O
investigated,O
as,O
it,O
could,O
make,O
subsequent,O
infection,CAUSE_OF_DEATH
with,O
SARSCoV,O
‐,O
2,NUMBER
more,O
severe,O
.49,NUMBER
The,O
Human,O
Challenge,O
Studies,O
may,O
accelerate,O
this,O
process,O
.,O
as,O
they,O
re,O
‐,O
quire,O
fewer,O
participants,O
and,O
shorter,O
follow,O
‐,O
up,O
time,O
than,O
the,O
usu,O
‐,O
al,O
effectiveness,O
and,O
safety,O
studies,O
.,O
In,O
these,O
studies,O
.,O
partici,O
‐,O
pants,O
get,O
infected,O
on,O
purpose,O
in,O
a,O
controlled,O
experimental,O
set,O
‐,O
ting,O
.,O
rather,O
than,O
waiting,O
for,O
the,O
infection,CAUSE_OF_DEATH
to,O
occur,O
naturally,O
.,O
Volunteers,O
are,O
young,O
.,O
healthy,O
and,O
living,O
in,O
areas,O
where,O
the,O
virus,O
is,O
circulating,O
.,O
They,O
would,O
be,O
monitored,O
and,O
receive,O
treatment,O
if,O
they,O
became,O
ill,O
.,O
The,O
two,NUMBER
main,O
limitations,O
of,O
this,O
proposal,O
are,O
a,O
),O
obtaining,O
evidence,O
of,O
effectiveness,O
in,O
a,O
specific,O
group,O
(,O
young,O
and,O
healthy,O
),O
other,O
than,O
the,O
group,O
most,O
in,O
need,O
of,O
the,O
vaccine,O
(,O
elderly,O
and,O
chronically,O
ill,O
),O
;,O
and,O
b,O
),O
the,O
risk,O
of,O
death,O
of,O
a,O
healthy,O
volunteer,O
.,O
even,O
if,O
small,O
.,O
since,O
there,O
is,O
no,O
effective,O
treatment,O
for,O
the,O
disease,CAUSE_OF_DEATH
.,O
Still,O
.,O
there,O
are,O
compelling,O
arguments,O
that,O
make,O
this,O
proposal,O
feasible,O
and,O
promising,O
.50,NUMBER
The,O
wearing,O
of,O
masks,O
by,O
the,O
entire,O
population,O
is,O
controversial,O
.,O
Its,O
use,O
is,O
de,O
‐,O
fended,O
by,O
the,O
precautionary,O
principle,O
.,O
which,O
says,O
that,O
in,O
cases,O
of,O
serious,O
or,O
irreversible,O
threats,O
to,O
health,O
or,O
ecosystems,O
.,O
rec,O
‐,O
ognizing,O
that,O
there,O
is,O
scientific,O
uncertainty,O
should,O
not,O
be,O
used,O
as,O
a,O
reason,O
to,O
postpone,O
preventive,O
measures,O
.51,NUMBER
If,O
on,O
the,O
one,NUMBER
hand,O
there,O
is,O
a,O
lack,O
of,O
robust,O
evidence,O
from,O
RCT,ORGANIZATION
.,O
on,O
the,O
other,O
hand,O
we,O
are,O
facing,O
a,O
highly,O
transmissible,O
disease,CAUSE_OF_DEATH
.,O
against,O
which,O
we,O
have,O
no,O
immunity,O
and,O
which,O
is,O
causing,O
deaths,O
and,O
collapse,O
in,O
health,O
systems,O
.,O
The,O
logic,O
would,O
be,O
that,O
the,O
mask,O
would,O
protect,O
the,O
oth,O
‐,O
er,O
.,O
because,O
the,O
user,O
would,O
not,O
expel,O
contaminated,O
droplets,O
if,O
she,O
were,O
an,O
asymptomatic,O
(,O
or,O
symptomatic,O
),O
carrier,O
.,O
However,O
.,O
it,O
can,O
be,O
argued,O
that,O
it,O
would,O
also,O
protect,O
the,O
user,O
.,O
as,O
it,O
would,O
be,O
a,O
bar,O
‐,O
rier,O
preventing,O
contaminated,O
droplets,O
from,O
the,O
other,O
reaching,O
the,O
users,O
mouth,O
and,O
nose,O
.,O
Due,O
to,O
the,O
lack,O
of,O
evidence,O
.,O
researchers,O
questioned,O
the,O
benefit,O
and,O
warned,O
about,O
the,O
possible,O
adverse,O
ef,O
‐,O
fects,O
related,O
to,O
the,O
wearing,O
of,O
masks,O
by,O
the,O
general,TITLE
public,O
.,O
such,O
as,O
its,O
misuse,O
and,O
the,O
false,O
sense,O
of,O
security,O
.,O
Mask,O
wearing,O
could,O
lead,O
to,O
relaxation,O
(,O
or,O
devaluation,O
),O
of,O
other,O
preventive,O
methods,O
.,O
such,O
as,O
social,O
distancing,O
and,O
hand,O
washing,O
.,O
52,NUMBER
Those,O
who,O
argue,O
in,O
favour,O
remind,O
that,O
no,O
RCT,MISC
has,O
been,O
performed,O
to,O
assess,O
the,O
ef,O
‐,O
fects,O
of,O
lockdown,O
or,O
hand,O
washing,O
either,O
.,O
Possibly,O
.,O
the,O
best,O
justification,O
in,O
favour,O
of,O
wearing,O
a,O
mask,O
.,O
even,O
in,O
the,O
absence,O
of,O
evidence,O
from,O
RCT,MISC
.,O
would,O
be,O
the,O
low,O
potential,O
for,O
harm,O
.,O
as,O
op,O
‐,O
posed,O
to,O
taking,O
drugs,CRIMINAL_CHARGE
without,O
evidence,O
from,O
RCT,ORGANIZATION
.,O
which,O
has,O
high,O
potential,O
for,O
harm,O
.,O
However,O
.,O
it,O
is,O
intriguing,O
and,O
frustrating,O
to,O
notice,O
the,O
enormous,O
amount,O
of,O
registered,O
RCTs,O
for,O
testing,O
drugs,CRIMINAL_CHARGE
compared,O
to,O
the,O
minimum,O
amount,O
for,O
evaluating,O
the,O
effect,O
of,O
masks,O
.,O
a,O
simple,O
and,O
inexpensive,O
intervention,O
.53.54,NUMBER
In,O
order,O
to,O
implement,O
any,O
strategy,O
aimed,O
to,O
control,O
the,O
pandemic,O
and,O
preserve,O
the,O
economy,O
.,O
the,O
country,O
needs,O
leadership,O
that,O
centralizes,O
and,O
coordinates,O
actions,O
.,O
Unfortunately,O
.,O
the,O
Brazilian,NATIONALITY
government,O
is,O
not,O
fulfilling,O
this,O
role,O
;,O
on,O
the,O
contrary,O
.,O
it,O
is,O
a,O
hindrance,O
.,O
This,O
negative,O
leadership,O
and,O
lack,O
of,O
coordination,O
are,O
causing,O
many,O
deaths,O
and,O
are,O
severely,O
damaging,O
the,O
lives,O
of,O
survivors,O
by,O
delaying,O
the,O
resuming,O
of,O
economic,O
and,O
social,O
activities,O
.,O
At,O
this,O
moment,O
it,O
is,O
not,O
possible,O
to,O
predict,O
when,O
the,O
first,ORDINAL
wave,O
of,O
this,O
pandemic,O
will,O
be,O
under,O
control,O
in,O
Brazil,COUNTRY
.,O
what,O
(,O
and,O
how,O
),O
economic,O
and,O
social,O
activities,O
will,O
be,O
compatible,O
with,O
pandemic,O
control,O
.,O
and,O
when,O
(,O
and,O
if,O
),O
there,O
will,O
be,O
specific,O
effective,O
vaccine,O
or,O
Brazilian,NATIONALITY
society,O
will,O
not,O
be,O
able,O
to,O
maintain,O
the,O
lockdown,O
for,O
a,O
long,O
period,O
.,O
Naturally,O
.,O
in,O
the,DATE
near,DATE
future,DATE
.,O
regardless,O
of,O
the,O
ad,O
‐,O
vice,O
from,O
scientists,O
.,O
doctors,O
reopen,O
.,O
A,O
lack,O
of,O
a,O
responsible,O
and,O
proactive,O
central,O
leadership,O
in,O
consonance,O
with,O
the,O
best,O
scien,O
‐,O
tific,O
evidence,O
.,O
increases,O
the,O
risk,O
of,O
a,O
tragedy,O
in,O
the,O
near,O
fu,O
‐,O
ture,O
.,O
Unless,O
we,O
take,O
urgent,O
action,O
.,O
there,O
may,O
be,O
an,O
economic,O
de,O
‐,O
bacle,O
.,O
social,O
unrest,O
and,O
a,O
slaughter,O
never,O
witnessed,O
by,O
current,DATE
generations,O
.,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,O
Strategies,O
to,O
deal,O
with,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
1,NUMBER
.,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
.,O
WHO,O
Di,O
‐,O
rector,O
‐,O
Generals,O
opening,O
remarks,O
at,O
the,O
media,O
briefing,O
on,O
COVID,O
‐,O
19,NUMBER
‐,O
11,DATE
March,DATE
2020,DATE
.,O
2020,DATE
Mar,DATE
4,DATE
.,O
Kimball,PERSON
A,O
.,O
Hatfield,PERSON
KM,O
.,O
Arons,PERSON
M,O
.,O
James,PERSON
A,PERSON
.,O
Taylor,PERSON
J,PERSON
.,O
Spicer,PERSON
K,PERSON
.,O
et,O
al,O
.,O
Asymptomatic,O
and,O
presymp,O
‐,O
tomatic,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infections,CAUSE_OF_DEATH
in,O
residents,O
of,O
a,O
long,O
‐,O
term,O
care,O
skilled,O
nursing,O
facility,O
‐,O
King,TITLE
County,LOCATION
.,O
Washington,STATE_OR_PROVINCE
.,O
March,DATE
2020,DATE
.,O
MMWR,ORGANIZATION
Morb,ORGANIZATION
Mortal,ORGANIZATION
Wkly,ORGANIZATION
Rep.,TITLE
2020,DATE
Apr,DATE
;,O
69,NUMBER
(,O
13,NUMBER
),O
:,O
377,NUMBER
‐,O
81,NUMBER
.,O
5,NUMBER
.,O
Wei,O
WE,O
.,O
Li,PERSON
Z,O
.,O
Chiew,PERSON
CJ,PERSON
.,O
Yong,PERSON
SE,PERSON
.,O
Toh,PERSON
MP,O
.,O
Lee,PERSON
VJ,O
.,O
Presymptomatic,O
transmission,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
‐,O
Singapore,COUNTRY
.,O
January,DATE
23,DATE
‐,O
March,DATE
16,DATE
.,DATE
2020,DATE
.,O
MMWR,PERSON
Morb,PERSON
Mortal,O
Wkly,O
Rep.,TITLE
2020,DATE
Apr,DATE
;,O
69,NUMBER
(,O
14,NUMBER
),O
:,O
411,NUMBER
‐,O
5,NUMBER
.,O
6,NUMBER
.,O
Wolfel,PERSON
R,PERSON
.,O
Corman,PERSON
VM,PERSON
.,O
Guggemos,PERSON
W,PERSON
.,O
Seilmaier,O
M,O
.,O
Zange,PERSON
S,PERSON
.,O
Muller,PERSON
MA,PERSON
.,O
et,O
al,O
.,O
Virological,O
assessment,O
of,O
hospitalized,O
patients,O
with,O
12,NUMBER
.,O
Kissler,O
SM,O
.,O
Tedijan,O
‐,O
to,O
C,O
.,O
Goldstein,PERSON
E,O
.,O
Grad,O
YH,O
.,O
Lipsitch,O
M.,O
Projecting,O
the,O
transmis,O
‐,O
sion,O
dynamics,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
through,O
the,O
13,NUMBER
.,O
Hallal,ORGANIZATION
PC,ORGANIZATION
.,O
Horta,PERSON
BL,O
.,O
Barros,ORGANIZATION
AJD,ORGANIZATION
.,O
Dellagostin,ORGANIZATION
OA,ORGANIZATION
.,O
Hartwig,PERSON
FP,O
.,O
Pellanda,ORGANIZATION
LC,ORGANIZATION
.,O
et,O
al,O
.,O
Evoluo,O
da,O
prevalncia,O
de,O
infeco,O
por,O
COVID,O
‐,O
19,NUMBER
no,O
14,NUMBER
.,O
Estado,O
do,O
Rio,PERSON
Grande,O
do,O
Sul,O
.,O
Secretaria,O
de,O
Planejamento,O
.,O
Oramento,PERSON
e,O
Gesto,O
.,O
Epi,O
‐,O
covid19,O
.,O
Epidemiologia,O
da,O
COVID,O
‐,O
19,NUMBER
no,O
Rio,O
16,NUMBER
.,O
Nadanovsky,PERSON
P.,PERSON
Nmero,PERSON
dirio,O
registrado,O
de,O
novas,O
mortes,O
pela,O
COVID,O
‐,O
19,NUMBER
nas,O
trs,O
primeiras,O
semanas,O
aps,O
a,O
primeira,O
morte,O
registrada,O
18,NUMBER
.,O
Nadanovsky,O
P.,O
Por,O
que,O
o,O
Brasil,PERSON
.,O
mesmo,O
depois,O
de,O
mais,O
de,O
quatro,O
semanas,O
de,O
confinamento,O
domiciliar,O
.,O
ainda,O
apresenta,O
aumento,O
no,O
19,NUMBER
.,O
Nadanovsky,PERSON
P.,PERSON
Est,PERSON
er,O
‐,O
rado,O
comparar,O
o,O
nmero,O
de,O
mortes,O
pela,O
COVID,O
‐,O
19,NUMBER
entre,O
pases,O
sem,O
considerar,O
o,O
tamanho,O
da,O
populao,O
em,O
cada,O
22,NUMBER
.,O
Thomas,PERSON
P.,PERSON
J,PERSON
‐,PERSON
value,O
as,O
‐,O
sessment,O
of,O
how,O
best,O
to,O
combat,O
Covid,O
‐,O
19,NUMBER
.,O
Nanotechnology,O
Percep,O
‐,O
tions,O
.,O
2020,DATE
;,O
16:16,TIME
‐,O
40,NUMBER
.,O
23,NUMBER
.,O
Mellan,ORGANIZATION
TA,ORGANIZATION
.,O
Hoeltgebaum,PERSON
HH,PERSON
.,O
Mishra,PERSON
S,O
.,O
Whittaker,PERSON
C,O
.,O
Schnekenberg,ORGANIZATION
RP,ORGANIZATION
.,O
Gandy,PERSON
A,O
.,O
et,O
al,O
.,O
Report,O
21,NUMBER
:,O
Estimat,O
‐,O
ing,O
COVID,O
‐,O
19,NUMBER
cases,O
and,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,NUMBER
Nadanovsky,O
P,O
.,O
Santos,O
APP,O
27,NUMBER
.,O
Alon,PERSON
U,PERSON
.,O
Milo,PERSON
R,PERSON
.,O
Yashiv,PERSON
E.,O
10,NUMBER
‐,O
4,NUMBER
:,O
How,O
to,O
reopen,O
the,O
economy,O
by,O
exploiting,O
the,O
Coronaviruss,MISC
weak,O
spot,O
.,O
2020,DATE
May,DATE
11,DATE
.,O
Available,O
from,O
:,O
28,NUMBER
.,O
Wu,O
Z,O
.,O
McGoogan,PERSON
JM,PERSON
.,O
Characteristics,O
of,O
and,O
Im,O
‐,O
portant,O
lessons,O
from,O
the,O
Coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
out,O
‐,O
break,O
in,O
China,COUNTRY
:,O
summary,O
of,O
a,O
report,O
of,O
72,NUMBER
314,NUMBER
cases,O
from,O
the,O
Chi,O
‐,O
nese,O
center,O
for,O
disease,CAUSE_OF_DEATH
control,O
and,O
prevention,O
.,O
JAMA,ORGANIZATION
.,O
2020,DATE
;,O
323,NUMBER
(,O
13,NUMBER
),O
:,O
1239,DATE
‐,O
1242,DATE
.,O
31,NUMBER
.,O
Kupferschmidt,O
K.,O
Preprints,O
bring,O
firehose,O
of,O
outbreak,O
data,O
.,O
Science,O
.,O
2020,DATE
;,O
367,NUMBER
(,O
6481,NUMBER
),O
:,O
963,NUMBER
‐,O
4,NUMBER
.,O
32,NUMBER
.,O
Majumder,PERSON
MS,STATE_OR_PROVINCE
.,O
Mandl,ORGANIZATION
KD,ORGANIZATION
.,O
Early,O
in,O
the,O
epidemic,O
:,O
impact,O
of,O
preprints,O
on,O
global,O
discourse,O
about,O
COVID,O
‐,O
19,NUMBER
transmissibility,O
.,O
Lancet,O
Glob,O
35,NUMBER
.,O
Bauchner,PERSON
H,O
.,O
Fontanarosa,PERSON
PB,O
.,O
Randomized,O
clinical,O
trials,O
and,O
COVID,O
‐,O
19,NUMBER
:,O
managing,O
expectations,O
.,O
JAMA,ORGANIZATION
.,O
2020,DATE
May,DATE
4,DATE
.,O
37,NUMBER
.,O
Thorlund,PERSON
K,O
.,O
Dorn,PERSON
L,O
.,O
Park,O
H,O
.,O
Hsu,PERSON
G,PERSON
.,O
Forrest,PERSON
JI,PERSON
.,O
Mills,PERSON
EJ,PERSON
.,O
A,O
real,O
‐,O
time,O
dash,O
‐,O
board,O
of,O
clinical,O
trials,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
Lancet,ORGANIZATION
Digital,ORGANIZATION
Health,ORGANIZATION
2020,DATE
39,NUMBER
.,O
Kalil,PERSON
AC,O
.,O
Treating,O
COVID,O
‐,O
19,NUMBER
‐,O
Off,O
‐,O
Label,O
Drug,O
Use,O
.,O
Compassion,O
‐,O
ate,O
Use,O
.,O
and,O
Randomized,O
Clinical,O
Trials,O
During,O
Pandemics,O
.,O
JAMA,ORGANIZATION
.,O
40,NUMBER
.,O
Ledford,PERSON
H.,PERSON
Chloroquine,PERSON
hype,O
is,O
derailing,O
the,O
search,O
for,O
coro,O
‐,O
navirus,O
treatments,O
.,O
Nature,O
.,O
2020,DATE
APR,DATE
;,O
580,NUMBER
(,O
7805,NUMBER
),O
:,O
573,NUMBER
.,O
41,NUMBER
.,O
Alexan,PERSON
‐,PERSON
der,O
PE,STATE_OR_PROVINCE
.,O
Debono,PERSON
VB,PERSON
.,O
Mammen,PERSON
MJ,PERSON
.,O
Iorio,PERSON
A,O
.,O
Aryal,PERSON
K,PERSON
.,O
Deng,PERSON
D,PERSON
.,O
et,O
al,O
.,O
COVID,O
‐,O
19,NUMBER
research,O
has,O
overall,O
low,O
methodological,O
quality,O
thus,O
42,NUMBER
.,O
Borba,ORGANIZATION
MGS,ORGANIZATION
.,O
Val,ORGANIZATION
FFA,ORGANIZATION
.,O
Sampaio,PERSON
VS,O
.,O
Alexandre,PERSON
MAA,PERSON
.,O
Melo,PERSON
GC,O
.,O
Brito,PERSON
M,O
.,O
et,O
al,O
.,O
Effect,O
of,O
high,O
vs,O
low,O
doses,O
of,O
chloroquine,O
diphosphate,O
as,O
adjunctive,O
therapy,O
for,O
patients,O
hospitalized,O
with,O
severe,O
acute,O
respiratory,O
syndrome,O
Coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
infection,CAUSE_OF_DEATH
:,O
a,O
ran,O
‐,O
domized,O
43,NUMBER
.,O
Pacheco,ORGANIZATION
RL,ORGANIZATION
.,O
Pachito,O
DV,O
.,O
Bagattini,ORGANIZATION
AM,ORGANIZATION
.,O
Oliveira,PERSON
Junior,PERSON
H,O
.,O
Riera,PERSON
R.,PERSON
Hidroxicloroquina,PERSON
e,O
cloroquina,O
para,O
COVID,O
‐,O
19,NUMBER
:,O
reviso,O
sistemtica,O
44,NUMBER
.,O
Pan,ORGANIZATION
American,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
.,O
World,O
Health,O
Or,O
‐,O
ganization,O
.,O
Ongoing,O
living,O
update,O
of,O
potential,O
COVID,O
‐,O
19,NUMBER
therapeu,O
‐,O
tics,O
:,O
summary,O
of,O
45,NUMBER
.,O
Riera,PERSON
R,PERSON
.,O
Bagattini,ORGANIZATION
AM,ORGANIZATION
.,O
Pachito,O
DV,O
.,O
Medeiros,PERSON
FC,ORGANIZATION
.,O
Brito,PERSON
GV,PERSON
.,O
Matuoka,PERSON
JY,PERSON
.,O
et,O
al,O
.,O
Heparinas,O
para,O
infeco,O
por,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
(,O
COVID,O
‐,O
19,NUMBER
),O
:,O
46,NUMBER
.,O
Riera,PERSON
R,PERSON
.,O
Pacheco,ORGANIZATION
RL,ORGANIZATION
.,O
Latorraca,LOCATION
COC,LOCATION
.,O
Fontes,PERSON
LE,O
.,O
Martimbianco,ORGANIZATION
ALC,ORGANIZATION
.,O
Remdesivir,O
para,O
infeco,O
por,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
Reviso,O
47,NUMBER
.,O
Liu,PERSON
M,O
.,O
Caputi,ORGANIZATION
TL,ORGANIZATION
.,O
Dredze,PERSON
M,O
.,O
Kesselheim,PERSON
AS,STATE_OR_PROVINCE
.,O
Ayers,O
JW,O
.,O
Internet,MISC
searches,O
for,O
unproven,O
COVID,O
‐,O
19,NUMBER
therapies,O
in,O
the,O
United,COUNTRY
States,COUNTRY
.,O
JAMA,ORGANIZATION
50,NUMBER
.,O
Eyal,PERSON
N,PERSON
.,O
Lipsitch,PERSON
M,O
.,O
Smith,ORGANIZATION
PG,ORGANIZATION
.,O
Human,O
challenge,O
studies,O
to,O
accelerate,O
Coronavirus,O
vaccine,O
licensure,O
.,O
J,O
Infect,O
Dis,O
.,O
2020,DATE
;,O
221,NUMBER
(,O
11,NUMBER
),O
:,O
1752,DATE
‐,O
6,NUMBER
.,O
Geneva,CITY
:,O
World,O
Health,O
Organiza,O
‐,O
tion,O
;,O
2004,DATE
.,O
52,NUMBER
.,O
Cheng,ORGANIZATION
KK,ORGANIZATION
.,O
Lam,PERSON
TH,O
.,O
Leung,PERSON
CC,O
.,O
Wearing,O
face,O
masks,O
in,O
the,O
community,O
during,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
:,O
altruism,O
and,O
soli,O
‐,O
darity,O
.,O
Lancet,O
.,O
53,NUMBER
.,O
Greenhalgh,PERSON
T,O
.,O
Schmid,ORGANIZATION
MB,ORGANIZATION
.,O
Czypionka,PERSON
T,O
.,O
Bassler,PERSON
D,O
.,O
Gruer,PERSON
L.,PERSON
Face,PERSON
masks,O
for,O
the,O
public,O
during,O
the,O
Covid,O
‐,O
19,NUMBER
crisis,O
.,O
BMJ,O
.,O
2020,DATE
;,O
369,NUMBER
:,O
m1435,O
.,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,NUMBER
Strategies,O
to,O
deal,O
with,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
.,O
Braz,PERSON
Oral,PERSON
Res,PERSON
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068,O
.,O
Where,O
is,O
read,O
:,O
Paulo,O
NADANOVSKY,O
(,O
a,O
),O
Ana,PERSON
Paula,PERSON
Pires,PERSON
dos,O
SANTOS,O
(,O
a,O
),O
Universidade,O
do,O
Estado,O
do,O
Rio,CITY
de,CITY
Janeiro,CITY
UERJ,LOCATION
.,O
Faculdade,ORGANIZATION
de,ORGANIZATION
Departamento,ORGANIZATION
de,ORGANIZATION
Odontologia,ORGANIZATION
Preventiva,ORGANIZATION
e,O
Comunitria,O
.,O
Rio,CITY
de,CITY
Janeiro,CITY
.,O
RJ,LOCATION
.,O
Brasil,LOCATION
.,O
It,O
should,O
read,O
:,O
Paulo,PERSON
NADANOVSKY,O
(,O
a,O
.,O
b,O
),O
Ana,PERSON
Paula,PERSON
Pires,PERSON
dos,O
SANTOS,O
(,O
c,O
),O
Fundao,PERSON
Oswaldo,PERSON
Cruz,PERSON
Fiocruz,O
.,O
Escola,ORGANIZATION
Nacional,ORGANIZATION
de,ORGANIZATION
Sade,ORGANIZATION
Pblica,ORGANIZATION
.,O
Departamento,O
de,O
Epidemi,O
‐,O
ologia,O
e,O
Mtodos,PERSON
Quantitativos,PERSON
em,O
Sade,O
.,O
Rio,CITY
de,CITY
Janeiro,CITY
.,O
RJ,O
.,O
Brazil,COUNTRY
.,O
Universidade,O
do,O
Estado,O
do,O
Rio,CITY
de,CITY
Janeiro,CITY
UERJ,LOCATION
.,O
Institu,O
‐,O
to,O
de,O
Medicina,ORGANIZATION
Social,ORGANIZATION
.,O
Departamento,O
de,O
Epidemiologia,O
.,O
Rio,LOCATION
de,LOCATION
Janeiro,PERSON
.,O
RJ,PERSON
.,O
Brazil,COUNTRY
.,O
Universidade,O
do,O
Estado,O
do,O
Rio,CITY
de,CITY
Janeiro,CITY
UERJ,ORGANIZATION
.,O
Faculdade,PERSON
de,PERSON
Odontologia,PERSON
.,O
Departamento,O
de,O
Odontologia,O
Pre,O
‐,O
ventiva,O
e,O
Comunitria,O
.,O
Rio,CITY
de,CITY
Janeiro,CITY
.,O
RJ,LOCATION
.,O
Brazil,COUNTRY
.,O
Braz,PERSON
.,O
Oral,O
Res,O
.,O
2020,DATE
;,O
34,NUMBER
:,O
e068err,O
